Articles
-
All
-
Scientific Reviews
-
EDM
-
Product Guides
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
Mammalian cells can also photosynthesize like plants! Photosynthesis can improve cell anabolism and exhibit good clinical effect in degenerative diseases (osteoarthritis).
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Structure of Lipid Droplets
2023-06-15
Huh? Lipid droplets? Organelles? In the past, biological data usually only show the traditional organelles, such as mitochondria, Golgi apparatus, endoplasmic reticulum, etc., lipid droplets are often not mentioned by people. Today, we will make a systematic explanation of lipid droplets, so that everyone has a clear understanding! -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
STZ Induced Diabetes Models
2024-06-13
Spotlight: How can STZ Help Diabetes Research? -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
Science’s 2023 Breakthrough: GLP-1R Agonists
2024-08-13
GLP-1RAs, which achieved great success in 2023 and draws people’s attention back to obesity treatments and GLP-1 therapies worldwide, was chosen as the breakthrough of year 2023 by Science [2]. -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
A New Form of Cell Death: PANoptosis!
-
Unlocking the Power of Intermittent Fasting: The 16+8 Method
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Have you ever noticed that after staying up late, your appetite—especially for high-calorie foods—gets out of control? If this sounds familiar, today’s article might offer some good news.
-
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Finding adipogenic induction media too expensive and tricky to prepare? This comprehensive guide to 3T3-L1 adipogenic differentiation simplifies the process, helping you achieve great results!
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
In the hunt for the next ‘GLP-1,’ amylin therapeutics, which have shown strong weight-loss results in clinical trials, have become a major focus for both multinational pharma and the scientific community.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
GLP-1 and Obesity Research
2026-08-14
Obesity substantially increases the risk of chronic diseases such as T2D and cardiovascular disease. The breakout success of GLP-1 therapies has spotlighted GLP-1R and a wave of emerging obesity targets. -
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
Research Progress of Type-2-Diabetes
2025-07-09
This review comprehensively analyzes the pathophysiological mechanisms underlying T2D, surveys current therapeutic strategies, and introduces commonly used disease modeling approaches to support translational research. -
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review provides an overview of GLP-1 biology and physiological functions, summarizes the development and clinical applications of GLP-1 receptor agonists, and discusses next-generation GLP-1–based therapeutic strategies.
-
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review summarizes the mechanisms of DSS-induced colitis, commonly used modeling approaches, and key considerations related to DSS molecular weight.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Explore next-generation obesity therapies from three perspectives: GLP-1-based multi-receptor agonists, oral GLP-1 strategies, and novel obesity targets.
-
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the evolution from GLP-1 mono-agonists to multi-receptor therapeutics and the expanding role of incretin-based therapies in precision metabolic medicine.
-
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Evolution of PCSK9 Inhibitors Modalities: From Monoclonal Antibodies to Oral Macrocyclic Peptides
2026-08-27
Review the biological basis of PCSK9, key therapeutic modalities, cardiovascular evidence, and future directions, including insights from the CORALreef clinical program. -
Explore the mechanisms of tumor immune evasion, dynamic checkpoint regulation, and the evolution of mechanism-driven combinations and patient stratification.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
Exosomes are nano-sized biovesicles released into surrounding body fluids after the fusion of multivesicular bodies with the plasma membrane. In this article, we will briefly introduce isolation, labeling and identification of exosomes. And the specific application of exosomes will also be mentioned.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
Nevanimibe is a selective and potent ACAT1 inhibitor. An excellent drug candidate in the treatment of adrenocortical cancer.
-
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM. Potently blocks the TNF response and RIP1-dependent inflammatory cytokine MIP-1β production.
-
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
Olutasidenib is a highly potent, selective inhibitor of mutant IDH1 that could be used in the treatment of AML or myelodysplastic syndrome (MDS).
-
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
TPCA-1, a Direct Dual Inhibitor of STAT3 and NF-κB, Regresses Mutant EGFR-Associated NSCLC
2019-07-15
TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding. -
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with anti-cancer activity. LSN 3213128 potently and specifically inhibits AICARFT.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
NXT629 is a potent, selective, and competitive PPAR-α antagonist and shows high selectivity over other nuclear hormone receptor.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BI-4924 is a Selective PHGDH Inhibitor
2019-08-23
BI-4924 is a lipophilic and highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal. -
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
FT113 is a potent and orally active fatty acid synthase inhibitor, with an IC50 of 213 nM for full-length recombinant human FAS, with anti-tumor activity.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
UPGL00004 is a allosteric glutaminase C inhibitor which strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines.
-
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1) R132 mutations.
-
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
TVB-3166 is an orally-available, reversible, and selective FASN inhibitor and it induces apoptosis, and inhibits in-vivo xenograft tumor growth.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
ASLAN003 is an orally active and potent inhibitor of hDHODH with antitumor activity, and it has the potential to be a first-in-class drug candidate in AML.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
DS18561882 is a highly potent, sozyme-selective methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor with a good oral pharmacokinetic profile.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
GNE-618 is a Orally Active NAMPT Inhibitor
2019-11-28
GNE-618 is an orally active NAMPT inhibitor and reduces tumor growth. GNE-618 depletes NAD levels and induces tumor cell death. -
Telaglenastat is a first-in-class, reversible, orally bioavailable glutaminase 1 splice variants (KGA and GAC) inhibitor. It shows antitumor activity.
-
UK 356618 is a Selective MMP-3 Inhibitor
2019-12-25
UK 356618 is a selective and potent inhibitor of MMP-3. UK 356618 exhibits potent anti-inflammatory and anti-cancer activity. -
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
GPP78 is a potent Nampt inhibitor. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells. GPP78 has anti-cancer and anti-tumor activity.
-
BAY-985 is an orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 and IKKε, respectively.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
CM10 is a potent and selective aldehyde dehydrogenase 1A family inhibitor and regulates metabolism and has anti-cancer activity.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
DC-5163 is a potent GAPDH inhibitor, can inhibit glycolysis pathway partially. DC-5163 selectively inhibits cancer cell proliferation and induces apoptosis.
-
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
OT-82 is a selective inhibitor of NAMPT. Selectively toxic to cells of hematopoietic origin. OT-82 is a promising antineoplastic agent.
-
TNP-351, an Antifolate, is a Dihydrofolate Reductase (DHFR) Inhibitor. Antifolates serve medical science well in neoplastic and non-neoplastic diseases.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
JX06 is a potent, selective and covalent inhibitor of PDK via covalently binding to a cysteine residue in an irreversible manner.
-
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with potent anti-cancer activity. IPI-9119 induces cell cycle arrest, apoptosis.
-
CAY10404 is a potent and highly selective COX-2 inhibitor. CAY10404 is a potent inhibitor of PKB/Akt and MAPK signalling pathways.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
BMS-P5 is an Orally Active PAD4 Inhibitor
2020-12-12
BMS-P5 is an orally active PAD4 inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model -
ML132, a potent and selective caspase 1 inhibitor with a unique selectivity pattern, is responsible for the proteolytic activation of IL-1β and IL-18.
-
CTPI-2 is a SLC25A1 inhibitor. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. Antitumor activity.
-
BI99179 is a Selective Type I FASN Inhibitor
2021-01-28
FASN is a key enzyme for lipogenesis and highly expressed in lipogenic tissues. BI99179 is a Selective Type I FASN Inhibitor. -
Fasentin inhibits GLUT-1 and GLUT-4 transporters. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity.
-
ML390 is a Potent DHODH Inhibitor
2021-02-24
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor and is an inducer of myeloid differentiation. -
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist. SB-332235 inhibits acute and chronic models of arthritis in the rabbit.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Vorasidenib is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor.
-
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Lumiracoxib is a COX-2 inhibitor. Lumiracoxib acts as nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
Ruxolitinib is a potent and selective JAK1/2 inhibitor and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
IMD-0354 is a Selective IKKβ Inhibitor
2021-11-09
IMD-0354 is a selective IKKβ inhibitor and potently inhibits NF-κB activity. IMD0354 has antitumor activity. -
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
Lonidamine, an antitumor agent and an indazole derivative, interferes with energy-yielding processes in cancer cells.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Zingerone is a natural orally active nontoxic methoxyphenol potent anti-inflammatory, antidiabetic, antioxidize, and anti-tumor properties.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Etrolizumab is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research
2022-11-05
Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody and has the potential for the research of inflammatory bowel disease. -
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
STF-31 is a potent ans selective inhibitor of GLUT1 that inhibit glucose uptake in renal cell carcinoma (RCC) 4 cells.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Talotrexin (PT523), a classic antifolate, is an RFC (reduced folate carrier) specific inhibitor and selectively inhibits RFC transport.
-
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
Ruxolitinib is an orally-active JAK1/2 inhibitor. Ruxolitinib has the potential for the research of myeloproliferative neoplasm (MPN).
-
BBO-11818 is a potent, selective, orally bioavailable, and noncovalent pan-KRAS inhibitor targeting multiple clinically relevant KRAS mutants in both ON and OFF states.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-15142A | Doxorubicin |
Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy.
Source: Streptomyces peucetius. |
ADC Payloads
Antibiotic
Bacterial
Topoisomerase
AMPK
HIV
Autophagy
Mitophagy
Apoptosis
HBV
Fluorescent Dye
Infection
Non-Small Cell Lung Cancer
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
711
|
| HY-15142 | Doxorubicin hydrochloride |
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.
Source: Streptomyces peucetius var. Caesius |
Topoisomerase
ADC Payloads
AMPK
Autophagy
Apoptosis
HIV
HBV
Mitophagy
Antibiotic
Bacterial
Fluorescent Dye
Non-Small Cell Lung Cancer
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
711
|
| HY-50895 | Gefitinib |
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
|
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Lipid Metabolism
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Metastatic Breast Cancer
SARS-CoV-2 Infection
|
222
|
| HY-15772 | Osimertinib |
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
|
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Glucose Metabolism
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
208
|
| HY-13629 | Etoposide |
Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.
|
Lung Cancer
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Viral Infection
Bacterial Infection
Digestive System Inflammation
|
191
|
| HY-A0004 | Decitabine |
Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell Apoptosis. Decitabine has potent anticancer activity.
|
Pancreatic Cancer
Viral Infection
Digestive System Inflammation
Urogenital Cancer
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
SARS-CoV-2 Infection
Rheumatoid Arthritis
|
183
|
| HY-50896 | Erlotinib |
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
|
|
147
|
| HY-10586 | 5-Azacytidine |
Lung Cancer
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Bacterial Infection
SARS-CoV-2 Infection
Rheumatoid Arthritis
|
142
|
|
| HY-10261 | Afatinib |
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Hepatitis C Virus Infection
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
113
|
| HY-L022M | FDA-Approved Drug Library Mini |
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,236 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.
|
|
101
|
| HY-50898 | Lapatinib |
Neurological, Eye or Ear Disease
Lung Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
HER-2 Positive Breast Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
100
|
|
| HY-L025 | Anti-Cancer Compound Library |
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
|
|
100
|
| HY-14596 | Genistein |
Neurological, Eye or Ear Disease
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Digestive System Inflammation
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
94
|
|
| HY-L030 | Human Endogenous Metabolite Compound Library |
The composition of endogenous metabolite compounds is affected by the upstream influence of the proteome and genome as well as environmental factors, lifestyle factors, medication, and underlying disease. Therefore, metabolites have been described as proximal reporters of disease because their abundances in biological specimens are often directly related to pathogenic mechanisms. In more recent years, metabolomics approach has been adopted or suggested to be used in various research areas including drug discovery, neurosciences, agriculture, food and nutrition, and environmental sciences.
MCE owns a unique collection of 765 human endogenous metabolites, all of which are derived from human issues. This library is a powerful tool for metabonomics research and metabolism-related drug discovery.
|
|
91
|
| HY-L026 | Clinical Compound Library |
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.
MCE owns a unique collection of 2,568 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.
|
|
90
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-16562 | Irinotecan |
Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.
|
Neurological, Eye or Ear Disease
Prostate Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
87
|
| HY-L078 | Gut Microbial Metabolite Library |
Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.
In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.
|
|
85
|
| HY-L134 | Anti-Aging Natural Product Library |
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.
Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.
|
|
85
|
| HY-L046 | Anti-Cardiovascular Disease Compound Library |
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.
MCE supplies a unique collection of 2,468 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.
|
|
84
|
| HY-L059 | Pyroptosis Compound Library |
Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.
MCE designs a unique collection of 2,034 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.
|
|
84
|
| HY-L060 | Cytoskeleton Compound Library |
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.
MCE designs a unique collection of 2,313 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.
|
|
84
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L083 | Anti-Cancer Metabolism Compound Library |
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.
MCE provides a unique collection of 3,806 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.
|
|
84
|
| HY-L180 | Mitophagy Compound Library |
Mitochondrial autophagy refers to the selective encapsulation and degradation of damaged mitochondria by cells through the autophagy mechanism, thereby maintaining mitochondrial and cellular homeostasis. The concept of mitochondrial autophagy has received extensive attention since it was proposed. Current studies have shown that the mechanisms of mitochondrial autophagy can generally be divided into two categories: Ubiquitin-dependent pathways and Ub-independent pathways. In addition, mitochondrial autophagy is a research hotspot related to the pathogenesis of neurodegenerative diseases, cardiovascular diseases, cancer, metabolic diseases and other clinical diseases. Therefore, high-throughput screening based on mitochondrial autophagy can effectively screen out compounds that are closely related to the occurrence of diseases and analyze their mechanisms.
MCE can provide a library of 655 mitophagy compounds, which can be used for drug development and mechanism research in cancer, immunity, infection and other hot research fields.
|
|
84
|
| HY-L188 | Anti-Brain Cancer Compound Library |
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.
MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
|
|
84
|
| HY-18258 | Berberine chloride |
Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties.
|
Topoisomerase
Autophagy
Bacterial
Reactive Oxygen Species (ROS)
Antibiotic
Endogenous Metabolite
Parasite
Inflammation or Immune System Disease
Lung Cancer
Viral Infection
Bacterial Infection
Parasitic Infection
SARS-CoV-2 Infection
|
83
|
| HY-L038 | Differentiation Inducing Compound Library |
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.
MCE Differentiation Inducing Compound Library contains a unique collection of 2,574 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.
|
|
83
|
| HY-L039 | Reprogramming Compound Library |
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.
MCE Reprogramming Compound Library contains a unique collection of 3,231 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.
|
|
83
|
| HY-L074 | Anti-Breast Cancer Compound Library |
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
|
|
83
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L088 | Angiogenesis-Related Compound Library |
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).
MCE offers a unique collection of 3,660 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.
|
|
83
|
| HY-L090 | Transcription Factor-Targeted Library |
Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.
MCE offers a unique collection of 2,569 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.
|
|
83
|
| HY-L103 | Anti-Colorectal Cancer Compound Library |
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.
Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research.
MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.
|
|
83
|
| HY-L119 | Potassium Channel Compound Library |
Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. There are four major classes of K channels: voltage-gated potassium channel, calcium-activated potassium channel, inwardly rectifying potassium channel and tandem pore domain potassium channel. There is growing evidence that dysfunction in potassium channels correlates with several diseases, such as chronic hypertension, diabetes, hypercholesterolemia and atherosclerosis, etc.
MCE Potassium Channel Compound Library consists of 337 potassium channel inhibitor and activators, which is a useful tool to discover drugs for cardiovascular diseases and potassium channel research.
|
|
83
|
| HY-L135 | Cancer Stem Cells Compound Library |
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.
Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.
MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.
|
|
83
|
| HY-L141 | Off-patent Drug Library |
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk.
MCE carefully prepared a unique collection of 2,921 off-patent drugs, which is a good choice for drug repurposing.
|
|
83
|
| HY-L155 | Mitochondrial Toxicity Compound Library |
Mitochondria, as the main place of energy supply in life, is essential to maintain normal life activities. Mitochondrial dysfunction is associated with common diseases, such as cardiovascular diseases, neurodegenerative diseases, diabetes and cancer. The heart, brain and liver rely heavily on mitochondrial function as the main organs for drug metabolism. In addition, mitochondria is also a target of many drugs, some of which induce organotoxicity by inducing mitochondrial toxicity.
MCE contains 545 mitochondrial toxic compounds, which can be used as tool compounds for drug development and disease mechanism research.
|
|
83
|
| HY-L161 | Cytokine Inhibitors Library |
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.
MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
|
|
83
|
| HY-L173 | Anti-Ovarian Cancer Compound Library |
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.
MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.
|
|
83
|
| HY-L184 | Anti-Gastric Cancer Compound Library |
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.
MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L225 | Cardiotoxic Compound Library |
Drug development is both expensive and time-consuming, with approximately one-third of drug discontinuations caused by severe adverse drug reactions (ADRs). Among these, drug-induced cardiotoxicity (DICT) is one of the primary reasons for late-stage clinical drug failures and market withdrawals. To date, cardiotoxicity has been observed in multiple drug classes, such as anticancer drugs, antipsychotics, antidepressants, antibiotics, and neurodegenerative disease medications. To reduce cardiac ADRs, it is crucial to determine the clinical relevance of DICT to treatment, elucidate the underlying molecular mechanisms, identify reliable biomarkers, and develop new diagnostic and therapeutic approaches.
MCE offers 260 cardiotoxicity compounds, including some FDA-approved drugs as well as inhibitors/blockers of the hERG potassium channel.
|
|
83
|
| HY-L249 | Lactylation Compound Library |
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.
MCE has assembled a collection of 6,182 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.
|
|
83
|
| HY-L250 | Lactic Acid Metabolite Compound Library |
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies.
The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.
|
|
83
|
| HY-L261 | Classic FDA-Approved Drug Library |
MCE Classic FDA-Approved Drug Library features a curated selection of marketed drugs that have achieved the highest prescription volumes and greatest clinical impact in global practice since 2006. The collection covers eight major therapeutic areas, including cardiovascular diseases, oncology, metabolic disorders, infectious diseases, central nervous system disorders, respiratory diseases, digestive system diseases, and immunological conditions. All compounds have been validated through long‑term clinical use and possess well‑defined molecular targets, well‑established pharmacokinetic properties, quantifiable efficacy endpoints, and comprehensive toxicological safety profiles.
The library currently contains 167 representative drugs and is designed to serve as an efficient tool for drug repurposing, phenotypic screening, mechanism‑of‑action studies, and combination therapy strategy development.
|
|
83
|
| HY-L923 | Ion Channel Lead-like Compound Library |
Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.
MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-13704 | SN-38 |
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 can bind to RPL15. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254).
|
|
79
|
| HY-16141 | Cilengitide |
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
|
|
75
|
| HY-16560 | Camptothecin |
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
|
Lung Cancer
Colorectal Cancer
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Fungal Infection
Digestive System Inflammation
|
73
|
| HY-P9907 | Trastuzumab |
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
Species: Human |
Non-Small Cell Lung Cancer
Luminal Breast Cancer
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
71
|
| HY-P9905 | Cetuximab |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
57
|
|
| HY-P9904 | Atezolizumab |
Colorectal Cancer
Liver Cancer
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
42
|
|
| HY-112288 | C188-9 |
C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia.
|
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Digestive System Inflammation
Obesity
|
37
|
| HY-141511 | Coppersensor 1 |
Coppersensor-1 (CS1) is a membrane-permeable fluorescent dye. Coppersensor-1 has a picomolar affinity for Cu+ with high selectivity over competing cellular metalions. Coppersensor-1 as a probe, can selective and sensitive detection of copper(I) ions (Cu+) in biological samples, including live cells. Coppersensor-1 can be used for the research of imaging of severe diseases such as cancer, cardiovascular disorders and neurogenerative diseases.
|
|
37
|
| HY-P9902 | Pembrolizumab |
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
37
|
| HY-19991 | BMS-1 |
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
Digestive System Inflammation
|
34
|
| HY-W018746 | EDTA disodium |
EDTA disodium salt, also known as ethylenediaminetetraacetic acid disodium, belongs to the chelating agent category, which is formed by chelating a central metal ion with four carboxylate groups and two amine groups. This compound, with its ability to bind and chelate metal ions such as calcium, magnesium and iron, is commonly used in a variety of applications, including industrial, medical and research settings. It is used as a preservative in food and beverage, as a stabilizer in medicine, as a chelating agent in water treatment, and as a reagent in biochemical and biomedical research. In addition, EDTA disodium salt has been studied for potential research effects such as improving heavy metal poisoning and cardiovascular disease.
|
|
31
|
| HY-P7077 | IL-2 Protein, Mouse |
IL-2 protein is mainly produced by activated CD4-positive helper T cells and plays an important role in immune response and tolerance. Binding to IL-2R induces downstream signaling through JAK1 and JAK3 phosphorylation, thereby activating various pathways, including STAT, PI3K, and MAPK. IL-2 Protein, Mouse is the recombinant mouse-derived IL-2 protein, expressed by E. coli.
Species: Mouse; Source: E. coli |
|
30
|
| HY-111558A | Bobcat339 hydrochloride |
Bobcat339 hydrochloride is a potent and selective cytosine-based inhibitor of TET enzyme, with the IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 hydrochloride is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.
|
|
29
|
| HY-111558 | Bobcat339 |
Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.
|
|
29
|
| HY-19745 | BMS-202 |
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
|
Neurological, Eye or Ear Disease
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
Digestive System Inflammation
|
27
|
| HY-P99144 | Anti-Mouse PD-1 Antibody (RMP1-14) |
|
27
|
|
| HY-135146 | GSK-3484862 |
GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma.
|
|
26
|
| HY-13631 | Exatecan |
Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.
|
|
24
|
| HY-13631A | Exatecan mesylate |
Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.
|
|
24
|
| HY-P7037 | IL-2 Protein, Human |
IL-2 Protein, Human activates STAT, PI3K and MAPK pathways. IL-2 Protein, Human increases NK-cell cytolytic activity as a T-cell growth factor. IL-2 Protein, Human regulates the proliferation of activated B-cells and regulatory T-cells. IL-2 Protein, Human is the recombinant human-derived IL-2 Protein, expressed by E. coli.
Species: Human; Source: E. coli |
|
24
|
| HY-P9903 | Nivolumab |
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Triple-Negative Breast Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
|
23
|
| HY-13962 | SGI-1027 |
SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC50s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.
|
Digestive System Disease
Leukemia/Lymphoma/Myeloma
Digestive System Inflammation
Rheumatoid Arthritis
|
20
|
| HY-P99145 | Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) |
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.
Species: Mouse |
|
20
|
| HY-13642 | RG108 |
RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC50=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences.
|
|
15
|
| HY-139664 | GSK-3685032 |
|
15
|
|
| HY-13765 | 6-Thioguanine |
6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
|
Digestive System Disease
Leukemia/Lymphoma/Myeloma
Viral Infection
Digestive System Inflammation
SARS-CoV-2 Infection
Rheumatoid Arthritis
|
14
|
| HY-13631D | DXd |
DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
|
|
14
|
| HY-N0390S1 | L-Glutamine-13C5 |
L-Glutamine-13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
13
|
| HY-113046 | 5-Methyltetrahydrofolic acid |
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
|
|
12
|
| HY-138298 | Trastuzumab deruxtecan (solution) |
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
|
12
|
| HY-138298A | Trastuzumab deruxtecan |
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
|
12
|
| HY-K1043 | CEPT Cocktail |
MCE CEPT Cocktail is composed of CET small molecules (Chroman 1, Emricasan and Trans-ISRIB) and Polyamine Solution, and can effectively enhance cell survival and promote clonal growth of genetically stable hPSCs. |
|
9
|
| HY-N1441 | Afzelin |
Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin.
|
Pancreatic Cancer
Bacterial Infection
Pain
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
|
8
|
| HY-W396714 | Succinic acid sodium |
Succinic acid sodium is a potent and orally active anxiolytic agent. Succinic acid sodium shows inhibitory effects on colonic epithelial cell proliferation in vivo. Succinic acid sodium can down-regulate the expression of KCNMB1 (potassium channel subunit β1) and TET1 (ten?eleven translocation 1). Succinic acid sodium can be used for gestational hypertension research.
|
|
7
|
| HY-P99032 | Monalizumab |
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Species: Human |
|
7
|
| HY-P9919 | Durvalumab |
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
7
|
|
| HY-108749 | Olive oil |
Olive oil (Cropure OL) is an oleaginous compound found in the fruit of the Olea europaea tree. Olive oil contains many phenolic components and exerts antioxidant activity. Olive oil exhibits hydroxyl radical scavenging, platelet aggregation inhibition and xanthine oxidase inhibitory activity. Olive oil can promote wound healing and relieve inflammation. Olive oil can be used for the research of inflammation, cancer, metabolic and cardiovascular disease, such as diabetic foot ulcers and inflammatory bowel disease.
|
Cancer
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
Inflammatory Bowel Disease
|
7
|
| HY-W127737 | Methylcobalamin hydrate |
Methylcobalamin Hydrate is a coenzyme required for methionine biosynthesis. Vitamins (hematopoiesis). It acts as a histamine receptor, Alzheimer study. Methylcobalamin is also used in the research of peripheral neuropathy, diabetic neuropathy, and as an initial research for amyotrophic lateral sclerosis. It can be used to prevent or research pathologies caused by vitamin B12 deficiency, such as pernicious anemia.
|
|
6
|
| HY-15934 | X-GAL |
X-GAL (BCIG) is a widely used chromogenic β-galactosidase substrate. X-GAL is a colorless compound until cleaved by β-galactosidase, at which point X-GAL turns to an insoluble and detectable blue compound, making X-GAL particularly useful in techniques such as blue-white screening for cloning in bacteria. X-GAL can also be used for detection of β-galactosidase activity.
|
|
6
|
| HY-14520 | Tetrahydrofolic acid |
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid.
|
|
6
|
| HY-N0007 | (E,E)-Bisdemethoxycurcumin |
(E,E)-Bisdemethoxycurcumin ((E,E)-Curcumin III) is a curcumin derivative with anti-inflammatory and anticancer activities.
|
|
5
|
| HY-N0368 | Linalool,98% (stabilized with MEHQ) |
Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities.
|
Digestive System Disease
Bacterial Infection
Depression
Autoimmune Disease
Digestive System Inflammation
Alzheimer's Disease
Parkinson's Disease
Hypertension
|
5
|
| HY-P9901 | Ipilimumab |
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Triple-Negative Breast Cancer
Metastatic Breast Cancer
Metastatic Melanoma
|
5
|
| HY-15142R | Doxorubicin hydrochloride (Standard) |
Doxorubicin hydrochloride (Standard) is the analytical standard of Doxorubicin hydrochloride. This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.
|
Reference Standards
Topoisomerase
ADC Payloads
AMPK
Autophagy
Apoptosis
HIV
HBV
Mitophagy
Antibiotic
Bacterial
Fluorescent Dye
|
5
|
| HY-P7037B | IL-2 Protein, Human (His) |
IL-2 protein is mainly produced by activated CD4-positive helper T cells and plays an important role in immune response and tolerance. Binding to IL-2R induces downstream signaling through JAK1 and JAK3 phosphorylation, thereby activating various pathways, including STAT, PI3K, and MAPK. IL-2 Protein, Human (His) is the recombinant human-derived IL-2 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
5
|
| HY-P70758 | IL-2 Protein, Human (HEK293, His) |
IL-2 protein is mainly produced by activated CD4-positive helper T cells and plays an important role in immune response and tolerance. Binding to IL-2R induces downstream signaling through JAK1 and JAK3 phosphorylation, thereby activating various pathways, including STAT, PI3K, and MAPK. IL-2 Protein, Human (HEK293, His) is the recombinant human-derived IL-2 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
5
|
| HY-K1054 | Blasticidin S, Sterile |
MCE Blasticidin S, Sterile (10 mg/mL) is a filtered and sterilized antibiotic solution that can be used directly in cell culture. Blasticidin S is a peptidyl nucleoside antibiotic isolated from Streptomyces griseochromogenes. It acts by blocking hydrolysis of peptidyl-tRNA induced by release factors and inhibits peptide bond formation. |
|
5
|
| HY-W009722 | Sodium diethylcarbamodithioate trihydrate |
Sodium diethylcarbamodithioate (Ditiocarb sodium) trihydrate is a copper reagent. The reaction with Cu2+ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethylcarbamodithioate trihydrate can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer.
|
|
4
|
| HY-N6712 | Thiolutin |
Thiolutin (Acetopyrrothin) is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases. Thiolutin can be produced by Streptomyces. Thiolutin inhibits AMSH (IC50 = 4 μM) and Rpn11 (IC50 = 0.53 μM). Thiolutin is a dual inhibitor of BRCC36 and the NLRP3 inflammasome, exhibiting anti-inflammatory effects. Thiolutin effectively suppresses the interaction between BRCC36 and HMGCR, leading to the inhibition of HCC growth. Thiolutin attenuates pyroptosis and NLRP3 inflammasome activation. Thiolutin markedly alleviates renal injury and inflammatory process in IgAN. Thiolutin is an anti-angiogenic compound which can ease Doxorubicin-induced cardiotoxicity (DOXIC).
Source: Streptomyces |
Antibiotic
Bacterial
Deubiquitinase
NOD-like Receptor (NLR)
DNA/RNA Synthesis
Pyroptosis
HMG-CoA Reductase (HMGCR)
|
4
|
| HY-N0390S9 | L-Glutamine-15N-1 |
L-Glutamine-15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
4
|
| HY-N0390S | L-Glutamine-15N |
L-Glutamine-15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
4
|
| HY-P7696 | CA125 Protein, Human (HEK293, His) |
CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.
Species: Human; Source: HEK293 |
|
4
|
| HY-K1041 | Seamless DNA Assembly Plus Kit |
MCE Seamless DNA Assembly Plus Kit contains an optimized mix of recombinase, reaction buffer, and additional cofactors that significantly improve the cloning efficiency and tolerance to impurities. This product can complete multiple DNA fragments recombination and takes only 5 minutes for single fragment, and the positive rate is more than 95%. |
|
4
|
| HY-108829A | Abatacept (powder) |
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
Species: Human |
|
3
|
| HY-P1032 | Angiotensin I (human, mouse, rat) |
Angiotensin I is a decapeptide hormone. Angiotensin I is the precursor of Angiotensin II (HY-13948). Angiotensin I can be used in the study of cardiovascular diseases such as hypertension and vasospasm.
|
|
3
|
| HY-D0885B | Phosphocreatine disodium |
Phosphocreatine (disodium) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine (disodium) enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine (disodium) normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine (disodium) provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway..
|
Breast Cancer
Pancreatic Cancer
Depression
Pain
Digestive System Inflammation
Glucose Metabolism
Parkinson's Disease
|
3
|
| HY-P99132 | Anti-Mouse CTLA-4 Antibody (9D9) |
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8+ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma.
Species: Mouse |
|
3
|
| HY-164992 | Trastuzumab vedotin |
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
|
|
3
|
| HY-D0885 | Phosphocreatine |
Phosphocreatine (creatine phosphate) is an organic compound found in vertebrate skeletal muscles. Phosphocreatine enhances antioxidant activity, and activates the TAK1 pathway to protect the heart. Phosphocreatine normalizing mitochondrial function and reducing oxidative stress via Akt mediated Nrf2/HO-1 pathway. Phosphocreatine provides renal protection by suppressing Apoptosis and ROS (Reactive Oxygen Species) generation through ERK mediated mediated Nrf-2/HO-1 pathway..
Source: skeletal muscles of vertebrates |
Breast Cancer
Pancreatic Cancer
Depression
Pain
Digestive System Inflammation
Glucose Metabolism
Parkinson's Disease
|
3
|
| HY-108829 | Abatacept |
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
Species: Human |
|
3
|
| HY-141598 | Datopotamab deruxtecan (solution) |
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer.
|
Prostate Cancer
Gastric Cancer
Pancreatic Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
|
3
|
| HY-P1723A | Spexin TFA |
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy.
|
|
2
|
| HY-P4911 | SDF-1α (human) |
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research.
|
|
2
|
| HY-13673 | Goserelin |
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
|
Metabolic or Endocrine Disease
Luminal Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
2
|
| HY-W014841 | Sodium hippurate, 98% |
Sodium hippurate, 98% is an orally active metabolite. Sodium hippurate, 98% can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Sodium hippurate, 98% decreases NRF2, MMP9 and leads to ROS accumulation. Sodium hippurate, 98% activates TGFβ/SMAD signaling. Sodium hippurate, 98% improves hyperuricemia and colitis. Sodium hippurate, 98% can also be used in cardiovascular disease research.
.
|
Metabolic or Endocrine Disease
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Pain
Cardiovascular Disease
Lung Fibrosis
Rheumatoid Arthritis
|
2
|
| HY-P1723 | Spexin |
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy.
|
|
2
|
| HY-P4911A | SDF-1α (human) TFA |
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research.
|
|
2
|
| HY-N0267 | Hypaconitine |
Hypaconitine inhibits the KCNH2 current with an IC50 of 8.1 nM, and exhibits cardiotoxicity. Hypaconitine inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cell through the inhibition of NF-κB nuclear translocation. Hypaconitine acts as the neuromuscular blocker. Hypaconitine is orally active.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Alzheimer's Disease
Obesity
|
2
|
| HY-N0353 | Curdione |
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
|
Ferroptosis
Apoptosis
Reactive Oxygen Species (ROS)
Autophagy
Glutathione Peroxidase
Keap1-Nrf2
Heme Oxygenase (HO)
TGF-β Receptor
Indoleamine 2,3-Dioxygenase (IDO)
Colorectal Cancer
Pancreatic Cancer
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
Lung Fibrosis
|
2
|
| HY-108801A | Aflibercept (VEGF Trap) |
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.
Species: Human |
|
2
|
| HY-108801 | Aflibercept |
Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.
Species: Human |
|
2
|
| HY-13673A | Goserelin acetate |
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
|
Metabolic or Endocrine Disease
Luminal Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
2
|
| HY-158301 | MY-1B |
MY-1B is a covalent inhibitor of the RNA Methyltransferase NSUN2 (IC50: 1.3 μM). MY-1B stereoselectively ligands active-site cysteine residues (C271) of NSUN2. MY-1B can stereoselectively and covalently bind to PSME1, disrupting the proteasome regulatory complex and downregulating the presentation of specific MHC-I subtypes.
|
|
2
|
| HY-K1041A | Seamless DNA Assembly Ultra Kit |
MCE Seamless DNA Assembly Ultra Kit is a next-generation recombinant cloning kit that allows the recombination of single or multiple DNA fragments in a single reaction. |
|
2
|
| HY-K6004 | Basement Membrane Matrix GFR |
MCE Growth Factor Reduced Basement Membrane Matrix (Phenol Red-Free) is primarily composed of natural basement membrane matrix extracted from mouse tumors and contains abundant extracellular matrix components and a variety of naturally occurring growth factors. This product is primarily designed for 3D organoid culture and other research applications requiring high-quality basement membrane matrix. The phenol red-free formulation avoids potential interference with experiments requiring subsequent colorimetric or color-based analysis. |
|
2
|
| HY-B1699 | Metrizoic acid |
Metrizoic acid (Metrizoate) is an ionic contrast medium. Metrizoic acid (Metrizoate) shows high osmolality and has a risk of inducing allergic reactions.
|
|
1
|
| HY-N9447 | Norbergenin |
Norbergenin is a polyphenolic isocoumarin derivative. Norbergenin acts as a non-competitive inhibitor of bovine adrenal tyrosine hydroxylase (TH) with a Ki value of 69.6 μM. Norbergenin inhibits lipopolysaccharide-induced inflammatory responses in macrophages by suppressing the activation of NF-κB, MAPK and STAT3, as well as blocking metabolic reprogramming. Norbergenin inhibits aluminum chloride-induced oxidative stress and apoptosis and restores neurocognitive parameters. Norbergenin scavenges ROS through multiple mechanisms and protects cell membranes from lipid peroxidation damage. Norbergenin can be used in research related to Alzheimer's disease, peptic ulcer and arthritis.
|
Free Radical Scavengers
Tyrosine Hydroxylase
Reactive Oxygen Species (ROS)
Apoptosis
NF-κB
p38 MAPK
STAT
|
1
|
| HY-N0368S | Linalool-d3 |
Linalool-d3 is the deuterium labeled Linalool. Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome.
|
|
1
|
| HY-120395 | UC-514321 |
UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.
|
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Digestive System Inflammation
Obesity
|
1
|
| HY-126030 | (+)-Syringaresinol |
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC50 of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia.
|
|
1
|
| HY-160638 | NSC-311068 |
|
1
|
|
| HY-N0390S5 | L-Glutamine-1-13C |
L-Glutamine-1-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
1
|
| HY-N2064 | Racanisodamine |
Racanisodamine is an orally active, non-selective Muscarinic Acetylcholine Receptor (mAChR) antagonist. Racanisodamine is a racemate of Anisodamine, and the two share similar pharmacological effects. Racanisodamine is an active ingredient of eye drops for myopia control. Racanisodamine can be used in research on myopia and late dumping syndrome.
|
|
1
|
| HY-W329357 | 15:0 Lyso PC |
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
|
|
1
|
| HY-122258 | NSC-370284 |
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Obesity
|
1
|
|
| HY-P4245 | D-Pro-Phe-Arg-Chloromethylketone |
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
|
|
1
|
| HY-12303 | OAC1 |
OAC1 is a potent Oct4 activator. OAC1 activates Oct4 and Nanog promoters and enhances induced pluripotent stem cells (iPSC) formation. OAC1 activates OCT4 through upregulation of HOXB4 expression. OAC1 increases transcription of the Oct4-Nanog-Sox2 triad and TET1. OAC1 facilitates the reprogramming of cells by enhancing efficiency and shortening the reprogramming time.
|
|
1
|
| HY-N0390S2 | L-Glutamine-d5 |
L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
1
|
| HY-P99117 | Cadonilimab |
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
Species: Human |
Inflammation or Immune System Disease
Gastric Cancer
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
|
1
|
| HY-103609 | Pyrene |
Pyrene is a polycyclic aromatic hydrocarbon (PAH) composed of four fused benzene rings. It has a distinct aromatic odor, produced by incomplete combustion of organic matter. Pyrene exhibits strong fluorescence, emitting in the blue region of the spectrum, making it useful as a probe for studying molecular interactions in solution and on surfaces. Pyrene is also used as a model compound for the study of PAHs in various environments and biological systems because of its ubiquity in these environments. However, long-term exposure to pyrene has been associated with potential health risks, including carcinogenicity and mutagenicity.
|
|
1
|
| HY-P99144A | Anti-Mouse PD-1 Antibody (S-5001) |
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.
Species: Mouse |
|
1
|
| HY-N0390S8 | L-Glutamine-15N2 |
L-Glutamine-15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
1
|
| HY-402410 | TETi76 |
TETi76 is an orally active TET family inhibitor with IC50 values ??of 1.5, 9.4 and 8.8 μM for TET1, TET2 and TET3, respectively. TETi76 competitively binds to the active site of TET enzymes, reduces cytosine hydroxymethylation and restricts clonal growth of TET2 mutants in vitro and in vivo, but does not affect the growth of normal hematopoietic precursor cells. TETi76 can be used for leukemia research.
|
|
1
|
| HY-P99675 | Ivonescimab |
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).
Species: Human |
|
1
|
| HY-P70718 | IL-2 Protein, Rat (HEK293, His) |
IL-2 Protein, produced by activated T-cells, NK cells, and helper T-cells, is crucial for immune response and tolerance. It binds to receptor complexes, activating downstream signaling pathways. IL-2 Protein acts as a growth factor, enhances NK-cell activity, promotes B-cell proliferation, and regulates regulatory T-cells. It also participates in differentiating effector T-cell subsets and memory CD8-positive T-cells. IL-2 Protein, Rat (HEK293, His) is the recombinant rat-derived IL-2 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Rat; Source: HEK293 |
|
1
|
| HY-K0533A | 2× High-Fidelity PCR Master Mix (with Dye) |
MCE 2× High-Fidelity PCR Master Mix (with Dye) is a new type of ready-to-use high-fidelity PCR amplification master mix.During the reaction, only template and primers need to be added to quickly and efficiently complete the PCR process, reducing the risk of contamination during operation. The 1 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base. |
|
1
|
| HY-K6105 | Human Gastric Cancer Organoid Kit |
MCE Human Gastric Cancer Organoid Kit contains Gastric Cancer Organoid Basal Medium A, Gastric Cancer Organoid Supplement B (50×), Gastric Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human gastric cancer organoid. |
|
1
|
| HY-KE8004 | Reverse Transcriptase |
Reverse Transcriptase is a reverse transcriptase that clones and expresses the deletion mutant RNase H- of M-MuLV through genetic recombination technology. |
|
1
|
| HY-P990031 | Dargistotug |
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.
Species: Human |
|
/
|
| HY-17038S1 | Agomelatine-d4 |
Agomelatine-d4 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
|
/
|
| HY-17503S2 | (S)-Metoprolol-d7 |
(S)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].
|
|
/
|
| HY-17503S1 | (R)-Metoprolol-d7 |
(R)-Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].
|
|
/
|
| HY-B0391S1 | Naftopidil-d5 |
Naftopidil-d5 is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia.
|
|
/
|
| HY-P5970 | DABCYL-TNF-α-EDANS (-4 to +6) (human) |
DABCYL-TNF-α-EDANS (-4 to +6) (human) is a FRET peptide substrate of tumor necrosis factor convertase (TACE).
|
|
/
|
| HY-P3598 | Substance P(1-4) |
Substance P(1-4) is a potent neurokinin receptors (NK-R) antagonist. Substance P(1-4) has regulation of normal hematopoiesis and inhibits endogenous erythroid colony (EEC) formation.
|
|
/
|
| HY-160261S | EP300/CBP-IN-2 |
EP300/CBP-IN-2 is a potent EP300/CBP inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer.
|
|
/
|
| HY-N17453 | (+)-Mornaphthoate E |
(+)-Mornaphthoate E is a growth inhibitor that suppresses cancer cell proliferation. It can be used in research on cancers such as lung cancer and breast cancer.
|
|
/
|
| HY-N17825 | Terrestroside A |
Terrestroside A is an anticancer agent. Terrestroside A inhibits the growth of various cancer cells in vitro. Terrestroside A can be used for the research of lung cancer, central nervous system cancer and breast cancer.
|
|
/
|
| HY-163587 | PRMT5-IN-39-d3 |
|
/
|
|
| HY-N21938 | 7-Acetyllycopsamine N-oxide |
7-Acetyllycopsamine N-oxide is a pyrrolizidine alkaloid N-oxide (PA N-oxide) that can be extracted from plants such as those in the Boraginaceae, Asteraceae or Compositae families. 7-Acetyllycopsamine N-oxide acts as a metabolic and potential toxic precursor. 7-Acetyllycopsamine N-oxide can be used in studies on component quantitative analysis, quality control of traditional Chinese medicine, and toxicological risk assessment for public health.
|
|
/
|
| HY-P11624 | PP-60 |
PP-60 is an apoptosis inducer. PP-60 inhibits the proliferation of cancer cells and induces cancer cell apoptosis. PP-60 exerts anti-tumor effects in nude mouse liver tumor models. PP-60 is applicable to research related to cancers such as liver cancer, lung cancer, and prostate cancer.
|
|
/
|
| HY-P2696 | EP 80317 |
EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease.
|
|
/
|
| HY-P2619 | BPP 5a |
BPP 5a is a bradykinin-potentiating peptide with vasorelaxant activity, which is found in Bothrops jararaca venom. BPP 5a is an angiotensin-converting enzyme (ACE) inhibitor with a Ki value of 400 nM. BPP 5a is promising for research of hypertension and cardiovascular diseases.
|
|
/
|
| HY-P4201 | JKC 301 |
JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking.
|
|
/
|
| HY-N19739 | Efrapeptin F |
Efrapeptin F is a mitochondrial complex V inhibitor and cytotoxic agent with in vivo antitumor activity. Efrapeptin F induces cell death in glucose-limiting conditions, with preferential cytotoxicity to nutrient-deprived cancer cells under hypoxic conditions. Efrapeptin F can be used for the research of pancreatic cancer, prostate cancer, breast cancer, central nervous system cancer, colon cancer, lung cancer, melanoma, ovarian cancer, kidney cancer, stomach cancer.
Source: Tolypocladium fungi |
|
/
|
| HY-P991292 | AB-3A4 |
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-D3158 | LGP-CL |
|
/
|
|
| HY-N18236 | 3β-Acetoxyl-atractylenolide I |
3β-Acetoxyl-atractylenolide I is a LSD1 inhibitor with an IC50 of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma.
|
Breast Cancer
Prostate Cancer
Gastric Cancer
Bladder Cancer
Acute Myeloid Leukemia
Esophageal Cancer
|
/
|
| HY-P11658 | Anticancer peptoid 1 |
Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer.
|
|
/
|
| HY-182259 | Montanastatin |
Montanastatin is an antitumor agent that can be isolated from the terrestrial actinomycete Streptomyces anulatus. Montanastatin inhibits the growth of various cancer cells. Montanastatin can be used in research related to lymphocytic leukemia, ovarian cancer, brain cancer, renal cancer, lung cancer, colon cancer and melanoma.
|
|
/
|
| HY-126412 | Neochamaejasmine A |
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer.
|
|
/
|
| HY-172166B | TRITC-lysine-dextran (MW 70kDa) |
TRITC-lysine-dextran (MW 70kDa) is a fluorescent label prepared by the conjugation of TRITC (HY-D0791), lysine and dextran. TRITC-lysine-dextran (MW 70kDa) serves multiple functions as an axonal tracer, non-viral nanocarrier and fixable fluorescent clonal marker. TRITC-lysine-dextran (MW 70kDa) undergoes anterograde and retrograde transport within axons of sensory neurons, and acts as a non-viral delivery system to precisely deliver biomolecules to neurons. TRITC-lysine-dextran (MW 70kDa) remains stably retained during histological preparation, thereby supporting continuous observation in live or fixed samples.
|
|
/
|
| HY-P1142S | GLP-2(rat) (Ala-13C3,15N) |
GLP-2(rat) (Ala-13C3,15N) is 13C and 15N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
|
|
/
|
| HY-N15524 | Thalictoside |
Thalictoside is found in A. squamosa L. Thalictoside is a sEH inhibitor (IC50: 20.2 µM). Thalictoside exerts anti-osteoporotic effects through an estrogen-like mechanism. Thalictoside can be used in the research of cardiovascular and urinary diseases.
|
|
/
|
| HY-N21573 | Milliamine A |
Milliamine A is an alkaloid ingenol ester derivative and a toxic substance that can be isolated from the dried roots of Euphorbia millii Ch. des Moulins. Milliamine A induces respiratory arrest caused by circulatory system damage, ptosis, diarrhea, weakened respiration, decreased body temperature, tremors, dyspnea, clonic-tonic convulsions, hemorrhage, and congestion of the lungs and spleen in mice.
|
|
/
|
| HY-70037S | Cinacalcet-d3 |
Cinacalcet-d3 is the deuterium labeled Cinacalcet. Cinacalcet (AMG 073) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
|
|
/
|
| HY-P99840 | Dalcinonacog alfa |
Dalcinonacog alfa is a recombinant FIX factor that can be used in the study of Haemophilia B.
|
|
/
|
| HY-N3283 | 6-Methylhydroxyangolensate |
6-Methylhydroxyyangolensate is a limonoid can be extracted from Khaya grandifoliola. 6-Methylhydroxyyangolensate has low antimalarial activity in vitro, with an IC50 of 21.59 μg/ml against P. falciparum (W2/Indochina clone).
|
|
/
|
| HY-N13380 | 6′‐O‐Galloylsalidroside |
6’-O-Galloylsalidroside is an active component of Rhodiola. 6’-O-Galloylsalidroside is promising for research of Alzheimer’s disease, lung diseases, cerebrovascular disease, diabetes, cardiovascular disease and aging-related diseases.
|
Neurological, Eye or Ear Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-D3182 | AldRed 588-A |
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
|
|
/
|
| HY-P0200 | RR-SRC |
RR-SRC is a substrate for src-tyrosine-specific protein kinase.
|
|
/
|
| HY-P992021 | WM-A1-3389 |
WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer.
Species: Human |
|
/
|
| HY-D2309 | IRDye700Dx (Maleimide) |
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells.
|
|
/
|
| HY-N10491 | Spongionellol A |
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer.
|
|
/
|
| HY-P991854 | Anti-iNKT Cell Antibody (6B11) |
Anti-iNKT Cell Antibody (6B11) recognizes an epitope on T cell receptor (TCR) V alpha 24-J alpha 18. Anti-iNKT Cell Antibody is specific for cloned and primary human but not rodent iNKT and the human invariant TCR-α. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
Species: Human |
|
/
|
| HY-N0390G | L-Glutamine (GMP) |
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
|
/
|
| HY-15150G | Bemcentinib (GMP) |
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
|
|
/
|
| HY-D3185 | AlDeSense AM |
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
|
|
/
|
| HY-107337S | Delapril-d3 hydrochloride |
Delapril-d3 (hydrochloride) is the deuterium labeled Delapril hydrochloride. Delapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases.
|
|
/
|
| HY-14249S1 | (R)-Bicalutamide-d5 |
(R)-Bicalutamide-d5 is deuterated labeled (R)-Bicalutamide (HY-108250). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.
|
|
/
|
| HY-P10621 | SHLP-1 |
SHLP-1 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-1 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer.
|
Cancer
Neurological, Eye or Ear Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N17753 | Protoneodioscin |
Protoneodioscin is a furostanol saponin found in the rhizomes of Dioscorea collettii var. hypoglauca. It exhibits selective activity against various cancer cell lines, including leukemia, but shows no activity against colon and renal cancer cells. Protoneodioscin can be used in research on cancers such as leukemia.
|
|
/
|
| HY-P992374 | huDMB5F3 |
huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonal antibody against human CD227/MUC1, with a Ka value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer.
Species: Human |
|
/
|
| HY-187270S | [U-15N]-ApoE4 |
[U-15N]-ApoE4 is the 15N-labeled ApoE4. Apolipoprotein E4 (ApoE4) is a significant genetic risk factor for Alzheimer's disease and is closely linked to cardiovascular diseases-such as atherosclerosis-through its influence on lipid metabolism. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
|
|
/
|
| HY-180885S | KRAS G12D-IN-35 |
KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer.
|
|
/
|
| HY-W653969 | Arotinolol-d5 hydrochloride |
Arotinolol-d5 (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases.
|
|
/
|
| HY-P4144 | Onvitrelin ucalontide |
Onvitrelin ucalontide (Phor18-LHRH (338613); EP-100) is a luteinizing hormone-releasing hormone (LHRH) receptor ligand. Onvitrelin ucalontide binds to functional LHRH receptors on cancer cells and mediates targeted cytotoxicity. Onvitrelin ucalontide reduces tumor volume, weight and the number of viable tumor cells in xenograft models. Onvitrelin ucalontide can be used for the research of breast cancer, ovarian cancer and prostate cancer.
|
|
/
|
| HY-170905S | MAT2A-IN-22 |
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects.
|
|
/
|
| HY-N3739 | Diacetonamine |
Diacetonamine is a sporulation inducing factor which can be extracted from soybean curd residue.
Source: Carteriospongia sp. |
|
/
|
| HY-P10790 | Breast cancer targeting peptide 18–4 |
Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively.
|
|
/
|
| HY-113221AS | Isovalerylcarnitine-d3 chloride |
Isovalerylcarnitine-d3 chloride is the deuterium labeled Isovalerylcarnitine chloride (HY-145542). Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
|
|
/
|
| HY-W104304 | 2-(3-Trifluoromethylphenyl)glycine hydrochloride |
2-(3-Trifluoromethylphenyl)glycine hydrochloride is a precursor of substituted 2-acetamido-5-aryl-l, 2,4-triazolones. Substituted 2-acetamido-5-aryl-l, 2,4-triazolones are dual V1a/V2 receptor antagonists and can be used in cardiovascular disease research.
|
|
/
|
| HY-187265S | [U-15N]-IL-6 |
[U-15N]-IL-6 is the 15N-labeled IL-6. IL-6 is a multifunctional cytokine that plays a crucial role in numerous physiological processes, including immune regulation, inflammatory responses, the control of hematopoiesis, and cell growth and differentiation. Alterations in IL-6 levels are closely associated with various disease states, such as autoimmune disorders, chronic inflammatory diseases, and certain types of tumors. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
|
|
/
|
| HY-P10293 | NQEQVSP |
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization.
|
|
/
|
| HY-120104 | Nitidanin |
Nitidanin ((±)-Nitidanin) is an antimalarial and antiviral compound that can be isolated from the wood of Xanthoxylum nitidun D. C. Nitidanin is shows IC50 values of 21.2 and 18.4 μM for D6 and W2 clones of Plasmodium falciparum, respectively. Nitidanin can be used for the research of malaria and virus infection.
|
|
/
|
| HY-12100S2 | Umeclidinium bromide-d7 |
Umeclidinium bromide-d7 (GSK573719A-d7) is the deuterium labeled Umeclidinium bromide (HY-12100). Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
|
|
/
|
| HY-P2185 | NFF-3 |
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity.
|
|
/
|
| HY-12100S | Umeclidinium-d5 bromide |
Umeclidinium-d5 (bromide) is the deuterium labeled Umeclidinium bromide. Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
|
|
/
|
| HY-D2260 | hMSCs-Neu perchlorate |
hMSCs-Neu perchlorate (Compound 4) is a fluorescent probe that converts hMSCs into neurons in the presence of fibroblast growth factor (FGF). hMSCs-Neu perchlorate may have important applications in neuropathology and neurodegeneration research.
|
|
/
|
| HY-W854549 | Heparin pentasaccharide |
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
|
|
/
|
| HY-N11081 | Hexanorcucurbitacin D |
Hexanorcucurbitacin D, a cucurbitacin, is a weak ecdysteroid receptor agonist. Hexanorcucurbitacin D can be isolated from Trichosanthes cucumeroides roots. Hexanorcucurbitacin D can be used for the research of cardiovascular disease (CVD).
|
|
/
|
| HY-P992470 | STT-5058 |
STT-5058 (ARGX-116; NN5058) is a human monoclonal antibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases.
Species: Human |
|
/
|
| HY-14520R | Tetrahydrofolic acid (Standard) |
Tetrahydrofolic acid (Standard) is the analytical standard of Tetrahydrofolic acid (HY-14520). This product is intended for research and analytical applications. Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid.
|
|
/
|
| HY-P99696 | Lerodalcibep |
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases.
|
|
/
|
| HY-P3742 | Tyrosinase (192-200), human mouse |
Tyrosinase (192-200), human mouse is a HLA-B*4403-restricted tyrosinase epitope with affinity for HLA-B4403 and HLA-B4402. Tyrosinase (192-200), human mouse binds to HLA-B*4403 to form a complex, which is recognized by the autologous cytotoxic T lymphocyte clone 22/31 derived from melanoma. Tyrosinase (192-200), human mouse binds to HLA-B4402 to form a complex, which is recognized by the CTL clone 329B/5 derived from healthy HLA-B4402 donors. Tyrosinase (192-200), human mouse is applicable to melanoma-related research.
|
|
/
|
| HY-N12041 | Axl-IN-16 |
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression.
Source: Hericium erinaceus,Monascus |
|
/
|
| HY-N18126 | 13b,14-Dihydrorutaecarpine |
13b,14-Dihydrorutaecarpine is a cytotoxin derived from dihydrorutaecarpine. 13b,14-Dihydrorutaecarpine exerts selective cytotoxicity against central nervous system (CNS) and prostate cancer cell lines (GI50=0.02 μM and 0.2 μM). 13b,14-Dihydrorutaecarpine can be used in the research of central nervous system (CNS) cancer, ovarian cancer, prostate cancer and renal cancer.
|
|
/
|
| HY-16910G | WIKI4 (GMP) |
|
/
|
|
| HY-W049802 | N-((Allyloxy)carbonyl)-N-methyl-L-alanine |
|
/
|
|
| HY-P991378 | MORAb-066 |
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research.
Species: Human |
|
/
|
| HY-P3169 | a-Helical Corticotropin Releasing Factor (9-41) |
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo.
|
|
/
|
| HY-15893G | DMOG (GMP) |
DMOG (GMP) is the GMP level of DMOG (HY-15893). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .
|
|
/
|
| HY-P992441 | PHST001 |
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.
Species: Human |
|
/
|
| HY-N15748 | Pelorol |
Pelorol ((-)-Pelorol) is a sesquiterpene found in the tropical marine sponge Dactylospongia elegans. Pelorol has weak antitrypanosomal activity with an IC50 of 17.4 μg/mL and antiplasmodial activity against Plasmodium falciparum clones K1 and NF54 with IC50 values of 786 ng/mL and 1911 ng/mL, respectively. Pelorol is promising for research of parasitic diseases, such as trypanosomiasis and malaria.
Source: Dactylospongia elegans |
|
/
|
| HY-12100S1 | Umeclidinium-d10 bromide |
Umeclidinium-d10 (bromide) is the deuterium labeled Umeclidinium bromide. Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
|
|
/
|
| HY-172836S | GLP-1 receptor agonist 17-d3 |
GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
|
|
/
|
| HY-P991574 | MEDI-5884 |
MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC50 of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its Kd values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.
Species: Human |
|
/
|
| HY-121855 | 1-Monoelaidin |
Monoeladin is an ester derivative of glycerin and oleic acid, which are commonly found in various vegetable and animal fats. Monoeladin has unique chemical properties that make it an important intermediate in the biosynthesis of other lipid molecules, especially in the formation of triglycerides and phospholipids. It also plays a role in food science as a partial replacement for saturated fat, which has been linked to an increased risk of heart disease.
|
|
/
|
| HY-B0835S | Fenobucarb-d3 |
Fenobucarb-d3 is the deuterium labeled Fenobucarb. Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis. Fenobucarb is a possible risk factor to cardiovascular and cerebrovascular systems in animals.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
/
|
| HY-P991133 | Efranarelaxin alfa |
Efranarelaxin alfa is a relaxin receptor agonist. Efranarelaxin alfa is promising for research of cardiovascular diseases and tissue repair.
|
|
/
|
| HY-N15525 | Arabinothalictoside |
Arabinothalictoside is found in A. squamosa L. Arabinothalictoside is a sEH inhibitor (IC50: 47.1 µM). Arabinothalictoside can be used in the research of cardiovascular and urinary diseases.
|
|
/
|
| HY-N18186 | Neojiangyouaconitine |
Neojiangyouaconitine is a diterpenoid alkaloid cytotoxin isolated from Aconitum soongaricum var. pubescens. Neojiangyouaconitine exhibits cytotoxic activity against human breast cancer, prostate cancer and lung cancer cells, with weak inhibitory effect on HeLa cells. Neojiangyouaconitine has the ability to kill specific tumor cell lines and can be applied to the research on the mechanisms of related cancers such as breast cancer, prostate cancer and lung cancer.
|
|
/
|
| HY-N18294 | (R,R)-Polysphorin |
(R,R)-Polysphorin is a neolignan antimalarial agent that is isolated from the dried leaves and stems of Rhaphidophora decursiva. (R,R)-Polysphorin inhibits the growth of chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum clones in vitro by mediating free radical damage to key cellular components via conjugated double bonds. (R,R)-Polysphorin also exhibits cytotoxicity against human oral epidermoid carcinoma cells.
|
|
/
|
| HY-P3747 | Hemagglutinin (48-68) |
Hemagglutinin (48-68) is the 48-68 fragment of influenza virus hemagglutinin. Hemagglutinin (48-68) can induce proliferation of the peptide specific T-cell clones.
|
|
/
|
| HY-P991417 | LYN00101 |
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research.
Species: Human |
|
/
|
| HY-N0322GL | Cholesterol (GMP Like, synthetic) |
Cholesterol (GMP Like, synthetic) is Cholesterol (synthetic) (HY-N0322E) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Cholesterol (synthetic) is a synthetic form of cholesterol. It is a lipid that sustains vital functions. Cholesterol (synthetic) can be used in research on cardiovascular diseases.
|
|
/
|
| HY-W116594 | X-GalNAc |
X-GalNAc is a chromogenic substrate for for N-acetyl-β-galactosidase, used to determine the presence or absence of a cloned DNA insert in bacteria growing on agar plates.
|
|
/
|
| HY-187271S | [U-15N]-ApoA1 |
[U-15N]-ApoA1 is the 15N-labeled ApoA1. Reduced serum levels of apolipoprotein A1 (ApoA1) are closely associated with cardiovascular diseases, such as coronary heart disease. This isotope can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.
|
|
/
|
| HY-N16523 | Ferruginoside C |
Ferruginoside C is a phenylethanoid. Ferruginoside C can be isolated from V. leiocarpum. Ferruginoside C shows potent alpha-glucosidase inhibitory activity with an IC50 of 19.93 μM. Ferruginoside C shows antioxidant activities. Ferruginoside C can be used in the research of cervical cancer, ovarian cancer, and colon cancer.
|
|
/
|
| HY-163591 | PRMT5-IN-36-d3 |
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research.
|
|
/
|
| HY-E70188 | N-Acetylgalactosamine-6-Sulfatase |
N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research.
|
|
/
|
| HY-D2004 | ATTO 488 streptavidin |
ATTO 488 streptavidin is a fluorescent reagent that specifically targets and binds to biotin (biotin), formed by the conjugation of ATTO 488 with streptavidin (HY-P3152). ATTO 488 streptavidin enables visualization of the activity of streptavidin immobilized on the surface of polymeric nanoparticles, or acts as a fluorescent probe to detect the selective binding and internalization process of anti-HB-EGF/NA with cells expressing HB-EGF (with no such effect on cells that do not express this receptor). ATTO 488 streptavidin effectively verifies the function of streptavidin conjugated to the surface of nanoparticles and is suitable for research related to atherosclerotic cardiovascular diseases.
|
|
/
|
| HY-139938S | (±)11(12)-EET methyl ester-d11 |
(±)11(12)-EET-d11 methyl ester (11,12-EET methyl ester-d11) is the deuterium labeled (±)11(12)-EET methyl ester (HY-139938). (±)11(12)-EET methyl ester (11,12-EET-methyl ester) is a methylated derivative of 11,12-epoxyeicosatrienoic acid (11,12-EET) (HY-130494). (±)11(12)-EET methyl ester cannot induce β-arrestin recruitment of the G protein-coupled receptor GPR132. (±)11(12)-EET methyl ester fails to enhance the expression of hematopoietic stem and progenitor cell (HSPC) markers. (±)11(12)-EET methyl ester can be used as a negative control molecule to study the structure-function relationship of 11,12-EET, facilitating the analysis of the role of the oxygenated fatty acid-GPR132 signaling axis in hematopoiesis.
|
|
/
|
| HY-P4720 | Interleukin-6 fragment (human) |
Interleukin-6 fragment (human) is a pleiotropic cytokine produced by lymphocytes and non-lymphocytes. The Interleukin-6 fragment (human) coding gene is located on human chromosome 7, with a length of approximately 5 kilobases. Interleukin-6 fragment (human) has potential applications in immune response, acute response, inflammation, tumors, and hematopoiesis.
|
|
/
|
| HY-P1142S1 | GLP-2(rat) (Ala-13C3,15N) TFA |
GLP-2(rat) (Ala-13C3,15N) TFA is 13C and 15N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
|
|
/
|
| HY-E70176 | N-Deacetylase/N-Sulfotransferase 1 |
N-Deacetylase/N-Sulfotransferase 1 is a sulfotransferase. N-Deacetylase/N-Sulfotransferase 1 modifies heparan sulfate-dependent growth factor and morphogen signalling.
|
|
/
|
| HY-B1834S1 | Megestrol-d5 |
Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause glucocorticoid-like effects and an increased risk of mental disorders.
|
|
/
|
| HY-P10715 | Fmoc-KCRGDK |
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
|
|
/
|
| HY-N19251 | Sulfobacin B |
Sulfobacin B is a competitive von Willebrand factor receptor GPIb/IX inhibitor with an IC50 of 2.2 μM. Sulfobacin B inhibits binding of von Willebrand factor to GPIb/IX in a competitive manner. Sulfobacin B can be used for the research of thrombosis.
Source: Chryseobacterium sp. |
|
/
|
| HY-P991583 | GP369 |
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.
Species: Human |
|
/
|
| HY-P0260 | p2Ca |
p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.
Source: tissues of H-2d mice |
|
/
|
| HY-105025 | Thymocartin |
Thymocartin (Thymopoietin II (32-35)) is the 32-35 fragment of the thymic factor (thymopoietin). Thymocartin has shown potential for immunodeficiency diseases research.
|
|
/
|
| HY-112935 | Nonacog alfa |
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B.
|
|
/
|
| HY-W248121 | Pyrromethene 567 |
Pyrromethene 567 is a commercially available BODIPY dye with a photodynamic cytotoxicity IC50 of 6.8 ± 1.8 μM.Pyrromethene 567 shows cytoplasmic localization and limited cellular uptake in cancer cells.Pyrromethene 567 can be used for the research of lung cancer.
|
|
/
|
| HY-W012974S | 3-Amino-2-methylpropanoic acid-d3 |
3-Amino-2-methylpropanoic acid-d3 is the deuterium labeled 3-Amino-2-methylpropanoic acid. 3-Amino-2-methylpropanoic acid could induce browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.
|
|
/
|
| HY-N12019 | Parishin K |
Parishin K is a cardioprotective agent obtained from the roots of Gastrodia elata Bl. Parishin K can be used in cardiovascular disease research.
|
|
/
|
| HY-179551S | (±)11(12)-EET-d11 Methyl ester |
(±)11(12)-EET-d11 Methyl ester is the deuterium labeled (±)11(12)-EET methyl ester (HY-139938). (±)11(12)-EET methyl ester is a methylated derivative of 11,12-epoxyeicosatrienoic acid (11,12-EET) (HY-130494). (±)11(12)-EET methyl ester cannot induce β-arrestin recruitment of the G protein-coupled receptor GPR132. (±)11(12)-EET methyl ester fails to enhance the expression of hematopoietic stem and progenitor cell (HSPC) markers. (±)11(12)-EET methyl ester can be used as a negative control molecule to study the structure-function relationship of 11,12-EET, facilitating the analysis of the role of the oxygenated fatty acid-GPR132 signaling axis in hematopoiesis.
|
|
/
|
| HY-103609R | Pyrene (Standard) |
Pyrene (Standard) is the analytical standard of Pyrene. This product is intended for research and analytical applications. Pyrene is a polycyclic aromatic hydrocarbon (PAH) composed of four fused benzene rings. It has a distinct aromatic odor, produced by incomplete combustion of organic matter. Pyrene exhibits strong fluorescence, emitting in the blue region of the spectrum, making it useful as a probe for studying molecular interactions in solution and on surfaces. Pyrene is also used as a model compound for the study of PAHs in various environments and biological systems because of its ubiquity in these environments. However, long-term exposure to pyrene has been associated with potential health risks, including carcinogenicity and mutagenicity.
|
|
/
|
| HY-W327449R | Feruloylputrescine (Standard) |
Feruloylputrescine is an oral active phenolamide found in citrus plants and formed through the decarboxylation of L-Arginine. Feruloylputrescine inhibits monooxygenase (cntA) and reductase (cntB) and trimethylamine production. Feruloylputrescine can be used for cardiovascular diseases research.
|
|
/
|
| HY-126363S | Ditiocarb-d10 |
Ditiocarb-d10 (Diethyldithiocarbamic acid-d10) is the deuterium labeled Ditiocarb (HY-126363). Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast cancer.
|
|
/
|
| HY-D2460 | Dextran-CY5.5 |
Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
|
|
/
|
| HY-121244 | Coumafuryl |
Coumafuryl is a kind of coumarin rodenticide. Coumafuryl inhibits the metabolic cycle of vitamin K that causes the interference with protein biosynthesis of vitamin K-dependent coagulant factors (II, VII, IX, and X factors) in the liver.
Source: human viscera |
|
/
|
| HY-B0391S2 | Naftopidil-d7 |
Naftopidil-d7 (KT-611-d7 ) is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia.
|
|
/
|
| HY-NP144 | Nerve Growth Factor 7S,murine submaxillary gland |
Nerve Growth Factor 7S,murine submaxillary gland is a high-molecular-weight α2β2γ2 neurotrophic factor complex isolated from murine submaxillary glands. Nerve Growth Factor 7S,murine submaxillary gland prevents the binding of active β-NGF dimers to neuronal receptors by sequestering the receptor-interacting region of β-NGF within the complex. Nerve Growth Factor 7S,murine submaxillary gland lacks neurotrophic activity due to the sequestration of β-NGF dimers and the occlusion of receptor-binding sites. Nerve Growth Factor 7S,murine submaxillary gland can be used in research related to neurodegenerative diseases.
|
|
/
|
| HY-N0272R | Eleutheroside E (Standard) |
Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis.
|
|
/
|
| HY-W778391 | Bisphenol A-13C2 |
Bisphenol A-13C2 is 13C labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.
|
|
/
|
| HY-W015466R | Acetylvaline (Standard) |
Acetylvaline (Standard) is the analytical standard of Acetylvaline (HY-W015466). This product is intended for research and analytical applications. Acetylvaline is a class of amino acid derivative metabolites. The expression abundance of Acetylvaline is upregulated under heat stress conditions; it participates in the regulation of amino acid biosynthesis, cysteine and methionine metabolic pathways, and mediates the physiological processes of antioxidant defense and energy metabolism reprogramming in Magallana sikamea. Acetylvaline can be released from acetylvalyl-RNA of Turnip Yellow Mosaic Virus (TYMV) by N‑acylaminoacyl‑tRNA hydrolase. Acetylvaline can be used in metabolism-related research.
|
|
/
|
| HY-114169S | WRG-28-d5 |
|
/
|
|
| HY-D2421 | DEAE-dex-Cy5 |
DEAE-dex-Cy5 is a fluorescent labeling reagent that combines Cy5 (HY-D0821) fluorescent dye, Dextran (dex) and Diethylaminoethyl (DEAE). Cy5 is a Cyanine dye (with a long wavelength about 662nm) that can be used for molecular labeling and microscopy imaging. Dex has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
|
|
/
|
| HY-129283BR | Goralatide acetate (Standard) |
Goralatide (acetate) (Standard) is the analytical standard of Goralatide (acetate). This product is intended for research and analytical applications. Goralatide, a natural tetrapeptide, is a physiological regulator of hematopoiesis. Goralatide can inhibit primitive haematopoietic cell proliferation.
|
|
/
|
| HY-129283B | Goralatide acetate |
Goralatide, a natural tetrapeptide, is a physiological regulator of hematopoiesis. Goralatide can inhibit primitive haematopoietic cell proliferation.
|
|
/
|
| HY-P10342 | Soystatin |
Soystatin is a peptide extracted from soy protein, whose main activity is to inhibit the absorption of cholesterol. Soystatin, as a peptide with significant cholic acid binding ability, can be used in the study of cardiovascular diseases.
|
|
/
|
| HY-D1876 | ZY-2 |
ZY-2 is a specific fluorescent probe for pyruvate kinase M2 (PKM2). ZY-2 can image in PKM2-positive cells in a time- and concentration-dependent manner. ZY-2 can be used for the detection of cancer cells.
|
|
/
|
| HY-144002 | RIBI-529 |
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
|
|
/
|
| HY-W1123936B | DBCO-PEG1000-FA |
DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
|
|
/
|
| HY-P11094 | Tet1-Cys peptide |
Tet1-Cys peptide is a peptide with the sequence HLNILSTLWKYRC. Tet1 (HLNILSTLWKYR) (HY-P10998) can specifically bind to the neuronal ganglioside receptor GT1b, possessing neuronal targeting capabilities. The Tet1-Cys peptide sequence has an added Cys, which can be used for drug conjugation for research on drug delivery.
|
|
/
|
| HY-D2460A | Dextran-CY5.5 (MW 10000) |
Dextran-CY5.5 (MW 10000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
|
|
/
|
| HY-D2460B | Dextran-CY5.5 (MW 40000) |
Dextran-CY5.5 (MW 40000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
|
|
/
|
| HY-17038S2 | Agomelatine-d3 |
Agomelatine-d3 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
|
/
|
| HY-P991721 | Ticalicibart |
Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor targeting PCSK9. Ticalicibart has anti-hyperlipidaemic activity. Ticalicibart can be used for cardiovascular disease like hypercholesterolaemia research.
Species: Human |
|
/
|
| HY-P10998 | Tet1 peptide |
Tet1 peptide is a peptide that specifically binds to neurons. Tet1 peptide binds to GT1B ganglioside and trisialoganglioside clostridial toxin receptor on the surface of neuronal cells, and can be used in peptide conjugation and drug delivery research.
|
|
/
|
| HY-N8218 | Homoeriodictyol 7-O-β-D-glucoside |
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activating factor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC50 of 0.8 μM.
|
|
/
|
| HY-N7788 | cis-2-Dodecenoic acid |
|
/
|
|
| HY-P4331 | Boc-Gln-Gly-Arg-AMC |
Boc-Gln-Gly-Arg-AMC is a fluorogenic substrate for kallikrein (PKa), coagulation factor XIIa (FXIIa) and coagulation factor XIa (FXIa). Boc-Gln-Gly-Arg-AMC enables fluorescence-based activity assays for PKa, FXIIa and FXIa.
|
|
/
|
| HY-P1985A | Notch 1 TFA |
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types.
|
|
/
|
| HY-10268S | Betrixaban-d6 |
Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor.
|
|
/
|
| HY-159061 | Antrodia Camphorata Extract |
|
/
|
|
| HY-W259888 | (R)-2-Hydroxysuccinic acid methyl ester |
(R)-2-Hydroxysuccinic acid methyl ester is a biochemical that can be used for the research of cancer or amyloidosis.
|
|
/
|
| HY-17503S | Metoprolol-d7 |
Metoprolol-d7 is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].
|
|
/
|
| HY-114128 | Turoctocog alfa pegol |
Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A.
Species: Human |
|
/
|
| HY-P990378 | Anti-Complement Factor P/Properdin Antibody |
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-70037AS | Cinacalcet-d3 hydrochloride |
Cinacalcet-d3 (hydrochloride) is the deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
|
|
/
|
| HY-P1985 | Notch 1 |
Notch 1 (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types.
|
|
/
|
| HY-NP143 | Nerve Growth Factor 2.5S,murine submaxillary gland |
Nerve Growth Factor 2.5S,murine submaxillary gland is a neurotrophic polypeptide and protein growth factor isolated from murine submaxillary glands. Nerve Growth Factor 2.5S,murine submaxillary gland increases the survival rate, phagocytic capacity and superoxide anion production level of mouse cells. Nerve Growth Factor 2.5S,murine submaxillary gland acts through cell membrane surface receptors to mediate the differentiation and maintenance of adrenergic neurons in the sympathetic nervous system. Nerve Growth Factor 2.5S,murine submaxillary gland loses its activity and undergoes dimer dissociation due to oxidation; it remains active after modification of specific tryptophan residues, while its tyrosine residues are not essential for activity. Nerve Growth Factor 2.5S,murine submaxillary gland may play a role in the inflammatory process.
|
|
/
|
| HY-N0007R | (E,E)-Bisdemethoxycurcumin (Standard) |
(E,E)-Bisdemethoxycurcumin (Standard) is the analytical standard of (E,E)-Bisdemethoxycurcumin. This product is intended for research and analytical applications. (E,E)-Bisdemethoxycurcumin ((E,E)-Curcumin III) is a curcumin derivative with anti-inflammatory and anticancer activities.
|
|
/
|
| HY-P11347 | NOTA-AUNP-12 |
NOTA-AUNP-12 is a PD-L1 antagonist (IC50=2.24×10−7 M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers).
|
|
/
|
| HY-P1822 | BDC2.5 mimotope 1040-31 |
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg+ T cells.
|
|
/
|
| HY-P9940A | Emicizumab (Anti-F9 & Factor IX) |
Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research.
Species: Human |
|
/
|
| HY-N10151 | Notoginsenoside R3 |
Notoginsenoside R3 is an active principle components of P. notoginseng. Notoginsenoside R3 act as a signaling molecule that is associated with various physiological effects. P. notoginseng and its components are used as traditional Chinese medicine for cardiovascular disease.
|
|
/
|
| HY-P990778 | Xirestomig |
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs).
Species: Human |
|
/
|
| HY-P99425 | Afelimomab |
Afelimomab (MAK 195F) is an anti-tumor necrosis factor monoclonal antibody. Afelimomab can be used for the research of sepsis.
Species: Human |
|
/
|
| HY-N8102 | Echinocystic acid 28-O-β-D-glucoside |
Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC50 of 10.61 nM.
|
|
/
|
| HY-N10742 | Maritimetin |
Maritimein is an aurone that can be isolated from Coreopsis tinctoria. Maritimein shows strong diphenyl(2,4,6-trinitrophenyl)iminoazanium (DPPH) radical-scavenging activity with an IC50 value of 4.12 μM. Maritimein can be used for the research of cardiovascular disease.
|
|
/
|
| HY-P991681 | Emaretamig |
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research.
Species: Human |
|
/
|
| HY-P99560 | Tadocizumab |
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
Species: Human |
|
/
|
| HY-50667S | Apixaban-13C,d3 |
|
/
|
|
| HY-145622 | Mecbotamab vedotin |
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162).
|
|
/
|
| HY-176785S | MCB-294 |
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
|
|
/
|
| HY-P99895 | Rulonilimab |
|
/
|
|
| HY-N6579 | Arvenin I |
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
|
|
/
|
| HY-N0390S3 | L-Glutamine-13C5,15N2,d5 |
L-Glutamine-13C5,15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N10663 | Kadsurenone |
Kadsurenone is a lignan with specific antagonistic activity against platelet-activating factor. Kadsurenone can be derived from the stem of Piper kadsura.
|
|
/
|
| HY-P990704 | Rilvegostomig |
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.
Species: Human |
|
/
|
| HY-P99298 | Lampalizumab |
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.
Species: Human |
|
/
|
| HY-Y1097S | Monomethyl phthalate-d4 |
Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule.
|
|
/
|
| HY-201263 | p-SCN-Bn-TCMC |
p-SCN-Bn-TCMC is a bifunctional chelator. Its cyclen backbone binds Hg2+, while its isothiocyanate group allows for conjugation to biomolecules. p-SCN-Bn-TCMC can be used in the research of prostate cancer.
|
|
/
|
| HY-W047191 | D-Glucono-1,4-lactone |
D-Glucono-1,4-lactone is a derivative of D-gluconic acid (HY-Y0569C). D-Glucono-1,4-lactone can be isolated from fruits, vegetables, honey, kombucha and wine. D-Glucono-1,4-lactone inhibits thrombin-induced arachidonic acid peroxidation and platelet activation. D-Glucono-1,4-lactone reduces superoxide anion production in thrombin-activated platelets. D-Glucono-1,4-lactone exerts antioxidant activity on platelets under oxidative stress conditions and prevents excessive platelet activation through antioxidant mechanisms. D-Glucono-1,4-lactone can be used in research related to cardiovascular diseases.
|
|
/
|
| HY-W357818 | Glycinexylidide |
Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local agent that can suppress or relieve pain, that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Obesity
Rheumatoid Arthritis
|
/
|
| HY-N0390S4 | L-Glutamine-5-13C |
L-Glutamine-5-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-W014226 | 4,4'-Dihydroxybenzophenone |
4,4'-Dihydroxybenzophenone is a type of phenolic ultraviolet absorber and a drug intermediate for synthesis of various anticancer active compounds (such as Sivifene (HY-14801)). 4,4'-Dihydroxybenzophenone binds to the active site of trypsin with binding constants (KA = 7.59 x 105 L/moL) and leads to abnormal structure of trypsin, suggesting that long-term intake may affect the digestive function of the human body. 4,4’-dihydroxybenzophenone has a relatively low toxicity to Chlorella vulgaris and a moderate toxicity to Daphnia magna.
|
|
/
|
| HY-W115609 | N-Phenylbenzamide |
N-Phenylbenzamide (N-Benzoylaniline) is a compound skeleton. N-Phenylbenzamide can be used for the researches of cancer and infection, such as enterovirus and cervical cancer.
|
|
/
|
| HY-P990303 | Anti-Mouse 2C TCR Antibody (1B2) |
Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR. Anti-Mouse 2C TCR Antibody (1B2) recognizes determinants on the variable regions of both the α and β subunits of the TCR (T cell receptor) expressed by the mouse cytotoxic T lymphocyte clone 2C. Anti-Mouse 2C TCR Antibody (1B2) can be used for the detections of immunofluorescence and flow cytometry.
Species: Mouse |
|
/
|
| HY-148748G | Butyzamide (GMP) |
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay.
|
|
/
|
| HY-121462 | Cyanine |
Cyanine is an excellent fluorescent core scaffold for constructing fluorescent probes. Covalent conjugation of Cyanine with other potent compounds can not only enhance their efficacy but also expand their application modes. Cyanine supports the development of cancer theranostic agents. Cyanine can be used in cancer research.
|
|
/
|
| HY-P99200 | Fulranumab |
|
/
|
|
| HY-148979 | 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine |
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine (SAPE) is a fluorescent reporter that specifically binds biotin. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine produces a detectable fluorescent signal to quantify target factors. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine can be used for the research of primary liver cancer, cervical cancer.
|
|
/
|
| HY-110397G | KP-457 (GMP) |
KP-457 (GMP) is KP-457 (HY-110397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture.KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC50s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.
|
|
/
|
| HY-P991222 | AMG-529 |
AMG-529 is a humanized monoclonal antibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases.
Species: Human |
|
/
|
| HY-DY1087 | Coppersensor 1 (solution) |
Coppersensor 1 (solution) is a membrane-permeable fluorescent dye. Coppersensor-1 has a picomolar affinity for Cu+ with high selectivity over competing cellular metalions. Coppersensor-1 as a probe, can selective and sensitive detection of copper(I) ions (Cu+) in biological samples, including live cells. Coppersensor-1 can be used for the research of imaging of severe diseases such as cancer, cardiovascular disorders and neurogenerative diseases.
Solvent and concentration: DMSO: 2 mM |
|
/
|
| HY-112486G | TA-316 (GMP) |
|
/
|
|
| HY-P990060 | Denecimig |
Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A.
Species: Human |
|
/
|
| HY-P99358 | Dezamizumab |
Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis.
Species: Human |
|
/
|
| HY-107024 | Osteogenic Growth Peptide (10-14) |
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor.
|
|
/
|
| HY-P4987 | TRAP-7 |
TRAP-7 is a thrombin receptor (PAR) activating peptide. TRAP-7 stimulates total inositol phosphate (IP) accumulation and phosphorylation of a specific endogenous substrate for activated PKC. TRAP-7 can be used in cardiovascular disease research.
|
|
/
|
| HY-P99166 | Vudalimab |
|
/
|
|
| HY-DY2002 | X-GAL (solution) |
X-GAL (BCIG) (solution) is a widely used chromogenic β-galactosidase substrate. X-GAL is a colorless compound until cleaved by β-galactosidase, at which point X-GAL turns to an insoluble and detectable blue compound, making X-GAL particularly useful in techniques such as blue-white screening for cloning in bacteria. X-GAL can also be used for detection of β-galactosidase activity.
Solvent and Concentration: DMF: 20 mg/mL |
|
/
|
| HY-P990785 | Etentamig |
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases.
Species: Human |
|
/
|
| HY-P990042 | Gotistobart |
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.
Species: Human |
|
/
|
| HY-P9940 | Emicizumab |
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
Species: Human |
|
/
|
| HY-P990690 | Volrustomig |
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.
Species: Human |
|
/
|
| HY-112803 | GNE-371 |
GNE-371 is a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like, with an IC50 of 10 nM for TAF1(2).
|
|
/
|
| HY-W015466 | Acetylvaline |
Acetylvaline is a class of amino acid derivative metabolites. The expression abundance of Acetylvaline is upregulated under heat stress conditions; it participates in the regulation of amino acid biosynthesis, cysteine and methionine metabolic pathways, and mediates the physiological processes of antioxidant defense and energy metabolism reprogramming in Magallana sikamea. Acetylvaline can be released from acetylvalyl-RNA of Turnip Yellow Mosaic Virus (TYMV) by N‑acylaminoacyl‑tRNA hydrolase. Acetylvaline can be used in metabolism-related research.
|
|
/
|
| HY-P990717 | Brenetafusp |
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3+ T cells to kill PRAME+ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer.
Species: Human |
|
/
|
| HY-78216 | 2-Thiooxamic acid ethyl ester |
|
/
|
|
| HY-W027544 | MCA |
|
/
|
|
| HY-P990569 | CM-24 |
CM-24 (MK-6018) is a highly selective humanized monoclonal antibody targeting CEACAM1/CD66a. CM-24 binds to the N-terminal domain of CEACAM1, blocks the CEACAM1-CEACAM1 interaction, relieves the co-inhibitory effect on CEACAM1-positive lymphocytes, and enhances the cytotoxic activity of TIL, LAK and NK cells against CEACAM1-positive tumor cells. CM-24 can be used in studies related to tumor immunology, tumor metastasis and thrombosis. For the isotype control of CM-24, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-P99950 | Evorpacept |
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
|
|
/
|
| HY-P990789 | Anti-Mouse CTLA-4 Antibody (9H10) |
Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer.
Species: Mouse |
|
/
|
| HY-P1212 | Cortistatin 14 (mouse, rat) |
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus.
|
|
/
|
| HY-W782083 | p-SCN-Bn-NOTA trihydrochloride |
p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as 64Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer.
|
|
/
|
| HY-P1654 | A20FMDV2 |
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma.
|
|
/
|
| HY-W327449 | Feruloylputrescine |
Feruloylputrescine is an oral active phenolamide found in citrus plants and formed through the decarboxylation of L-Arginine. Feruloylputrescine inhibits monooxygenase (cntA) and reductase (cntB) and trimethylamine production. Feruloylputrescine can be used for cardiovascular diseases research.
|
|
/
|
| HY-129763 | Di-4-ANEPPS |
Di-4-ANEPPS is a voltage-sensitive dye that acts on voltage-gated ion channels (such as sodium channels) and inhibits sodium current, significantly reducing sodium current density, although specific values like IC50 remain unclear. It mainly binds to the voltage-sensitive regions on the cell membrane, changing its fluorescence properties to reflect membrane potential changes and thus affecting the function of ion channels to exert its activity. This substance can be used in cardiovascular research, such as the electrophysiology of cardiomyocytes, myocardial ischemia, and the effects of drugs on cardiomyocytes. It is of great value in evaluating drug cardiotoxicity and exploring the mechanisms of arrhythmias.
|
|
/
|
| HY-13442AS | Eribulin-d3 mesylate |
Eribulin-d3 (mesylate) is a deuterium labeled Eribulin mesylate. Eribulin mesylate is a microtubule targeting agent that is used for the research of cancer.
|
|
/
|
| HY-Y1887 | Cottonseed oil |
Cottonseed oil is an edible oil extracted from the seeds of cotton (Gossypium hirsutum). Its fatty acid composition includes 26-35% saturated fatty acids, 42-52% polyunsaturated fatty acids, and 18-24% monounsaturated fatty acids. Cottonseed oil is regarded as an Insecticide, as it is used to protect the trunks of apple trees from damage by the apple clearwing moth. Cottonseed oil possesses anti-inflammatory and cardioprotective properties. It also has extensive applications in many fields such as biofuels, animal husbandry, cosmetics, agriculture, and chemical industry.
|
|
/
|
| HY-N0390S6 | L-Glutamine-13C5,15N2 |
L-Glutamine-13C5,15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
|
Isotope-Labeled Compounds
mGluR
Ferroptosis
Environmental Pollutants
Endogenous Metabolite
HIF/HIF Prolyl-Hydroxylase
mTOR
STAT
NF-κB
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P99189 | Cixutumumab |
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.
Species: Human |
Colorectal Cancer
Prostate Cancer
Liver Cancer
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Large Cell Lung Carcinoma
HER-2 Positive Breast Cancer
Metastatic Breast Cancer
|
/
|
| HY-NP004 | Cobra Venom Factor |
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.).
|
|
/
|
| HY-156002 | LUNA18 |
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer.
|
|
/
|
| HY-P9986 | Tiragolumab |
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.
Species: Human |
Respiratory Disease
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
/
|
| HY-131498 | Mca-PLGL-Dpa-AR-NH2 |
MOCAc-PLGL (Dpa) AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) is a synthetic fluorescent substrate mainly used for in vitro enzymatic activity assays of MMP-7 (detection at 393 nm after excitation at 328 nm). MOCAc-PLGL (Dpa) AR is specifically cleaved and hydrolyzed by MMP-7 at the Gly-Leu peptide bond, allowing enzymatic activity to be monitored via fluorometry or HPLC (DMSO is usually added to ensure sufficient dissolution when determining kinetic parameters). MOCAc-PLGL (Dpa) AR is used to accurately evaluate the catalytic activity and pH dependence of recombinant mature human MMP-7 in vitro. MOCAc-PLGL (Dpa) AR is suitable for research on the mechanisms of tumor metastasis and invasion, particularly in fields such as prostate cancer, colon cancer, lung cancer and breast cancer.\n
|
|
/
|
| HY-NP165 | Advanced glycation end products |
Advanced glycation end products (AGEs) are a series of stable compounds generated through non-enzymatic reactions between reducing sugars and proteins, lipids, or nucleic acids. Advanced glycation end products are often used as targets to evaluate the inhibitory effects of anti-glycation compounds. Advanced glycation end products can be applied to research on diabetes, cardiovascular and cerebrovascular diseases, inflammation, aging, and other conditions.
|
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P9918 | Tremelimumab |
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.
Species: Human |
Inflammation or Immune System Disease
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
/
|
| HY-P10925 | Zolucatetide |
Zolucatetide (FOG-001;I-66) is a potent β-catenin inhibitor with an IC50 of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer.
|
|
/
|
| HY-P70775 | IL-2 Protein, Human (C145S) |
IL-2 protein is mainly produced by activated CD4-positive helper T cells and plays an important role in immune response and tolerance. Binding to IL-2R induces downstream signaling through JAK1 and JAK3 phosphorylation, thereby activating various pathways, including STAT, PI3K, and MAPK. IL-2 Protein, Human (C145S) is the recombinant human-derived IL-2 protein, expressed by E. coli , with tag free and C145S mutation.
Species: Human; Source: E. coli |
|
/
|
| HY-P73188 | IL-2 Protein, Canine (C147S) |
IL-2 Protein, produced by activated T-cells, NK cells, and helper T-cells, is crucial for immune response and tolerance. It binds to receptor complexes, activating signaling pathways. IL-2 Protein acts as a growth factor, enhances NK-cell activity, promotes B-cell proliferation, and regulates regulatory T-cells. It also participates in differentiating effector T-cell subsets and memory CD8-positive T-cells. IL-2 Protein, Canine (C147S) is the recombinant canine-derived IL-2 protein, expressed by E. coli , with tag free and C147S mutation.
Species: Canine; Source: E. coli |
|
/
|
| HY-P70793 | TrkB Protein, Human (HEK293, His) |
The TrkB protein is a key receptor tyrosine kinase that plays a key role in central and peripheral nervous system development. It regulates neuronal survival, proliferation, migration, differentiation, synapse formation, and plasticity. TrkB Protein, Human (HEK293, His) is the recombinant human-derived TrkB protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P74237 | Coagulation Factor XIV/PROC Protein, Human (HEK293, His) |
Coagulation Factor XIV/PROC is a vital vitamin K-dependent serine protease regulating blood coagulation. Active Protein C inactivates factors Va and VIIIa in the presence of calcium ions and phospholipids, maintaining the intricate balance of coagulation pathways. Its protective effect on endothelial cell barrier function underscores a broader impact on vascular integrity. Coagulation Factor XIV/PROC Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XIV/PROC protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor XIV/PROC Protein, Human (HEK293, His) is 443 a.a., with molecular weight of 56-64 & 45 kDa, respectively.
Species: Human; Source: HEK293 |
|
/
|
| HY-P7037A | IL-2 Protein, Human (CHO) |
IL-2 Protein, Human (CHO) is a CHO cell derived adjunctive immunotherapeutic agent to treat tuberculosis (TB).
Species: Human; Source: CHO |
|
/
|
| HY-P71043 | SNCG Protein, Human |
SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P704698 | IL-2 Protein, Human (HEK293) |
IL-2 protein is mainly produced by activated CD4-positive helper T cells and plays an important role in immune response and tolerance. Binding to IL-2R induces downstream signaling through JAK1 and JAK3 phosphorylation, thereby activating various pathways, including STAT, PI3K, and MAPK. IL-2 Protein, Human (HEK293) is the recombinant human-derived IL-2 protein, expressed by HEK293, with tag free.
Species: Human; Source: HEK293 |
|
/
|
| HY-P72436 | TrkB Protein, Mouse (HEK293, His) |
TrkB protein, also known as tropomyosin receptor kinase B, consists of a non-catalytic isoform. Unlike its catalytic isoform, the noncatalytic isoform of TrkB lacks intrinsic kinase activity. TrkB Protein, Mouse (HEK293, His) is the recombinant mouse-derived TrkB protein, expressed by HEK293 , with C-His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P73462 | TrkB Protein, Human (HEK293, His-Fc) |
The TrkB protein is a key receptor tyrosine kinase that plays a key role in central and peripheral nervous system development. It regulates neuronal survival, proliferation, migration, differentiation, synapse formation, and plasticity. TrkB Protein, Human (HEK293, His-Fc) is the recombinant human-derived TrkB protein, expressed by HEK293 , with C-hFc,C-10*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P78551 | GMP IL-2 Protein, Human (solution) |
IL-2 protein is mainly produced by activated CD4-positive helper T cells and plays an important role in immune response and tolerance. Binding to IL-2R induces downstream signaling through JAK1 and JAK3 phosphorylation, thereby activating various pathways, including STAT, PI3K, and MAPK. GMP IL-2 Protein, Human is the recombinant human-derived IL-2 protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P71928 | TFF1 Protein, Human |
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human is the recombinant human-derived TFF1 protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P703091 | BRCA1 Protein, Human |
BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli, with tag free labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P7677 | BIN2 Protein, Human (His) |
BIN2 Protein, Human (His) is a recombinant human bridging integrator 2 (BIN2) with a His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P73461 | TrkB Protein, Canine (HEK293, His) |
TrkB Protein is a neurotrophic factor receptor and a member of the tropomyosin receptor kinase family. TrkB Protein has high affinity for brain-derived neurotrophic factor (BDNF) and plays a role in various physiological functions of neurons, including cell survival and differentiation. TrkB Protein has carcinogenic activity. TrkB Protein, Canine (HEK293, His) is the recombinant canine-derived TrkB protein, expressed by HEK293 , with C-His labeled tag.
Species: Canine; Source: HEK293 |
|
/
|
| HY-P73574 | TrkB Protein, Rat (HEK293, His, solution) |
TrkB is a key receptor tyrosine kinase that coordinates multiple neuronal processes in the central and peripheral nervous systems.As a receptor for BDNF and NTF4, it regulates survival through NTF3. TrkB Protein, Rat (HEK293, His, solution) is the recombinant rat-derived TrkB protein, expressed by HEK293 , with C-His labeled tag.
Species: Rat; Source: HEK293 |
|
/
|
| HY-P72054 | RCVRN Protein, Human (sf9, His-Myc) |
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (sf9, His-Myc) is the recombinant human-derived RCVRN protein, expressed by sf9 insect cells , with N-10*His, C-Myc labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P71778 | RCVRN Protein, Human (P.pastoris, His) |
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (P.pastoris, His) is the recombinant human-derived RCVRN protein, expressed by P. pastoris , with N-His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P73575 | TrkB Protein, Rat (HEK293, Fc) |
TrkB is a key receptor tyrosine kinase that coordinates multiple neuronal processes in the central and peripheral nervous systems.As a receptor for BDNF and NTF4, it regulates survival through NTF3.TrkB Protein, Rat (HEK293, Fc) is the recombinant rat-derived TrkB protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Rat; Source: HEK293 |
|
/
|
| HY-P73576 | TrkB Protein, Canine (HEK293, Fc) |
TrkB Protein is a neurotrophic factor receptor and a member of the tropomyosin receptor kinase family. TrkB Protein has high affinity for brain-derived neurotrophic factor (BDNF) and plays a role in various physiological functions of neurons, including cell survival and differentiation. TrkB Protein has carcinogenic activity. TrkB Protein, Canine (HEK293, Fc) is the recombinant canine-derived TrkB protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Canine; Source: HEK293 |
|
/
|
| HY-P76849 | CSAG1 Protein, Human (HEK293, Fc) |
CSAG1 Protein is a potential key player in maintaining centrosome integrity during mitosis, impacting chromosome segregation. The mechanisms underlying its contribution to centrosome stability require elucidation. Its putative involvement highlights significance in mitosis-related cellular events. Further research is essential to unravel precise details of CSAG1's function and its implications for centrosome integrity during mitosis. CSAG1 Protein, Human (HEK293, Fc) is the recombinant human-derived CSAG1 protein, expressed by HEK293 , with N-hFc labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P73700 | PRAC Protein, Human (His-SUMO) |
PRAC Protein exhibits high expression in the prostate, rectum, and distal colon, with weaker expression in the bladder. Its prominence in prostate cancer cell lines suggests a potential link to prostate cancer pathology. The tissue-specific expression emphasizes PRAC Protein's potential roles in normal physiological processes and cancer contexts. PRAC Protein, Human (His-SUMO) is the recombinant human-derived PRAC protein, expressed by E. coli , with N-His, N-SUMO labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P74236 | Coagulation Factor XIV/PROC Protein, Mouse (HEK293, His) |
Factor XIV/PROC protein (or protein C) is an important vitamin K-dependent serine protease that regulates blood clotting.Protein C plays a crucial role in inactivating factors Va and VIIIa and regulating the coagulation cascade in the presence of calcium ions and phospholipids.Coagulation Factor XIV/PROC Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor XIV/PROC protein, expressed by HEK293 , with C-His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P703092 | BRCA2 Protein, Human (HEK293, His, Strep, Flag) |
BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293, with Strep, His, Flag labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P706289 | ¹⁵N-Labeled Apolipoprotein E/APOE (His) |
Species: Human; Source: E. coli |
|
/
|
| HY-P80862 | Phospho-TrkA/B (Tyr490/Tyr516) Antibody (YA139) |
Phospho-TrkA/B (Tyr490/Tyr516) Antibody (YA139) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-TrkA/B (Tyr490/Tyr516).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P80360 | TrkB Antibody (YA026) |
|
/
|
|
| HY-P86790 | BRCA2 Antibody (YA6483) |
BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P86827 | CTAG1B Antibody (YA6520) |
CTAG1B Antibody (YA6520) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CTAG1B.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P811127 | Recoverin Antibody |
Recoverin Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Recoverin.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P80862A | Phospho-TrkA/B (Tyr490/Tyr516) Antibody (YA139)(PBS only) |
Phospho-TrkA/B (Tyr490/Tyr516) Antibody (YA139) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-TrkA/B (Tyr490/Tyr516).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P811296 | CTAG1B Antibody |
CTAG1B Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CTAG1B.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P83052 | CEP55 Antibody (YA2797) |
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P83052A | CEP55 Antibody (YA2797)(PBS only) |
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.
Host: Rabbit; Reactivity: Human, Rat |
|
/
|
| HY-P86253 | NABC1 Antibody (YA5945) |
NABC1 Antibody (YA5945) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NABC1.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P86710A | G-CSF Antibody (YA6402)(PBS only) |
|
/
|
|
| HY-P86753 | MUC16 Antibody (YA6445) |
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P86753A | MUC16 Antibody (YA6445)(PBS only) |
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P87366 | BLCAP Antibody (YA7049) |
BLCAP Antibody (YA7049) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to BLCAP.
Host: Mouse; Reactivity: Human, Rat |
|
/
|
| HY-P86710 | G-CSF Antibody (YA6402) |
|
/
|
|
| HY-P87855 | Trk B Antibody (YA7540) |
|
/
|
|
| HY-K0253 | Heparin Agarose 6FF |
MCE Heparin Agarose 6FF is suitable for the separation and purification of heparin-binding biomolecules, including antithrombin III, coagulation factors, other plasma proteins, DNA-binding proteins, lipoproteins, protein synthesis factors, nucleic acid-related enzymes, and steroid receptors. |
|
/
|
| HY-K0254 | Blue Agarose 6FF |
MCE Blue Agarose 6FF can be used for the purification of biological macromolecules such as albumin, interferons, nucleotide-dependent enzymes (e.g., kinases, dehydrogenases), α2-macroglobulin, and coagulation factors. |
|
/
|
| HY-K1043A | Polyamine Supplement (1000×) |
MCE Polyamine Supplement (1000×) can be used as a component of the CEPT Cocktail in combination with Emricasan, Chroman 1, and trans-ISRIB to enhance the survival of pluripotent stem cells (PSCs) and promote single-cell clonal expansion. In addition, this supplement improves the viability of PSCs and their differentiated derivatives during cryopreservation, organoid culture, single-cell cloning, and genome editing, thereby enhancing the robustness and reproducibility of downstream applications. |
|
/
|
| HY-K2112 | HOLO Human Tumor Necrosis Factor-α (TNF-α) Detection Kit |
MCE HOLO Human Tumor Necrosis Factor-α (TNF-α) Detection Kit is a homogeneous luminescence-based assay used for the quantitative detection of human TNF-α concentrations in biological samples such as buffer solutions, cell culture supernatants, or serum. |
|
/
|
| HY-K2113 | HOLO Human Tumor Necrosis Factor-β (TNF-β) Detection Kit |
MCE HOLO Human Tumor Necrosis Factor-β (TNF-β) Detection Kit is a homogeneous luminescence-based assay used for the quantitative detection of human TNF-β concentrations in biological samples such as buffer solutions, cell culture supernatants, or serum. |
|
/
|
| HY-K2114 | HOLO Mouse Tumor Necrosis Factor-α (TNF-α) Detection Kit |
MCE HOLO Mouse Tumor Necrosis Factor-α (TNF-α) Detection Kit is a homogeneous luminescence-based assay used for the quantitative detection of mouse TNF-α concentrations in biological samples such as buffer solutions, cell culture supernatants, or serum. |
|
/
|
| HY-K3030 | Ham's F-12K (Kaighn's) |
Ham’s F-12K Medium was originally designed for the culture of primary human hepatocytes and differentiated rat and chicken cells. It is particularly suitable for single-cell cloning of Chinese hamster ovary (CHO) cells under serum-free conditions. When supplemented with serum, it can also be used for the culture of various other mammalian cell types, including chondrocytes and rat prostate epithelial cells. |
|
/
|
| HY-K6003 | Basement Membrane Matrix GFR (Phenol Red) |
MCE Growth Factor Reduced Basement Membrane Matrix (with Phenol Red) is primarily composed of natural basement membrane matrix extracted from mouse tumors and contains abundant extracellular matrix components and a variety of naturally occurring growth factors. This product is primarily designed for 3D organoid culture and other research applications requiring high-quality basement membrane matrix. |
|
/
|
| HY-K6009 | Basement Membrane Matrix GFR&HC |
MCE Basement Membrane Matrix GFR&HC (Growth Factor Reduced, High Concentration) is primarily composed of natural basement membrane matrix extracted from mouse tumors, is suitable for cell cultures that need to reduce growth factor induction and studies related to growth factors, signaling pathways, etc. |
|
/
|
| HY-K6021 | CEPT Cocktail Plus (1000×) |
MCE CEPT Cocktail Plus (1000×) is a composite supplement specifically formulated for pluripotent stem cell culture. Through synergistic effects, it inhibits oxidative damage, blocks apoptotic pathways, and regulates protein translation, significantly reducing cellular stress levels through multiple targets. This dramatically improves the survival rate and cloning efficiency of pluripotent stem cells. |
|
/
|
| HY-K6101 | Human Breast Cancer Organoid Kit |
MCE Human Breast Cancer Organoid Kit contains Breast Cancer Organoid Basal Medium A, Breast Cancer Organoid Supplement B (50×), Breast Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human breast cancer organoid. |
|
/
|
| HY-K6103 | Human Small Cell Lung Cancer Organoid Kit |
MCE Human Small Cell Lung Cancer Organoid Kit contains Small Cell Lung Cancer Organoid Basal Medium A, Small Cell Lung Cancer Organoid Supplement B (50×),Small Cell Lung Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human small cell lung cancer organoid. |
|
/
|
| HY-K6104 | Human Colorectal Cancer Organoid Kit |
MCE Human Colorectal Cancer Organoid Kit contains Colorectal Cancer Organoid Basal Medium A, Colorectal Cancer Organoid Supplement B (50×), Colorectal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human colorectal cancer organoid. |
|
/
|
| HY-K6107 | Human Cervical Cancer Organoid Kit |
MCE Human Cervical cancer Organoid Kit contains Cervical cancer Organoid Basal Medium A, Cervical cancer Organoid Supplement B (50×), Cervical cancer Organoid Supplement C (250×). This product can be used to efficiently construct human cervical cancer organoid. |
|
/
|
| HY-K6108 | Human Esophageal Cancer Organoid Kit |
MCE Human Esophageal Cancer Organoid Kit contains Esophageal Cancer Organoid Basal Medium A, Esophageal Cancer Organoid Supplement B (50×), Esophageal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human esophageal cancer organoid. |
|
/
|
| HY-K6109 | Human Endometrial Cancer Organoid Kit |
MCE Human Endometrial Cancer Organoid Kit contains Endometrial Cancer Organoid Basal Medium A, Endometrial Cancer Organoid Supplement B (50×), Endometrial Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human endometrial cancer organoid. |
|
/
|
| HY-K6110 | Human Pancreatic Cancer Organoid Kit |
MCE Human Pancreatic Cancer Organoid Kit contains Pancreatic Cancer Organoid Basal Medium A, Pancreatic Cancer Organoid Supplement B (50×), Pancreatic Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human pancreatic cancer organoid. |
|
/
|
| HY-K6123 | Human Ovarian Cancer Organoid Kit |
MCE Human Ovarian Cancer Organoid Kit includes a basic culture medium for ovarian cancer organoids, as well as culture supplements, and is designed for the effective construction of human ovarian cancer organoids. |
|
/
|
| HY-K6126 | Human Kidney Cancer Organoid Kit |
MCE Human Kidney Cancer Organoid Kit includes a basic culture medium for Kidney Cancer organoids, as well as culture supplements, and is designed for the effective construction of human Kidney Cancer organoids. |
|
/
|
| HY-K6303 | Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit |
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies. |
|
/
|
| HY-KE8001 | Phi29 DNA Polymerase |
Phi29 DNA Polymerase is a mesophilic DNA polymerase cloned from Bacillus subtilis phage Phi29. |
|
/
|
| HY-KE8009 | Taq DNA Ligase |
This enzyme is a DNA ligase cloned from Thermus thermophilus HB8. It is expressed in E. coli using genetic recombination technology and purified and isolated multiple times. |
|
/
|
Targets/Pathways










































































































































































































































